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Introduction
Two important groups of patients for the gastroenterologist and hepatologist are patients 
with inflammatory bowel diseases (IBDs) and liver diseases. The two most common IBDs 
are Crohn’s disease (CD) and ulcerative colitis (UC), and they are characterized by relaps-
ing inflammation of the gastrointestinal tract. In CD the entire gastrointestinal tract can be 
involved, while in UC the inflammation is limited to the colon. The prevalence in Europe and 
North America of CD is about 50 to 200/100,000 and of UC about 120 to 200/100,000.1 
Patients with IBD may have a complicated disease course with a high need for immuno-
suppressants and surgery; CD patients with small bowel disease have a 70-80% chance 
of requiring surgery and 20-30% of UC patients need a colectomy.1 The cause of IBD is 
thought to originate from a dysregulated immune system, but exact mechanisms are largely 
unknown. This dysregulated immune system is probably influenced by environmental factors 
and the genetic background. The last decade a still increasing number of genetic variants 
have been found to be associated with IBD. However, studies investigating interaction be-
tween these genetic variants and environmental factors are scarce.
The other important group is patients with liver diseases. The most prevalent liver diseases 
in Europe and North America are non-alcoholic fatty liver diseases, alcoholic liver diseases, 
viral hepatitis (Hepatitis B and C), primary sclerosing cholangitis, primary biliary cirrhosis 
and autoimmune hepatitis. All these liver diseases can lead to cirrhosis. Orthotopic liver 
transplantation (OLT) is an accepted therapy for end-stage liver disease. The prognosis of 
recipients has increased over the last decades with a 1-year survival rate of 85% and a 
5-year survival rate of 75%. The most important causes of morbidity and mortality after 
OLT are malignancies and cardiovascular diseases. Therefore, one of the main goals of the 
follow-up of recipients after OLT should be prevention and early detection of malignancies 
and cardiovascular diseases. Smoking is a notorious risk factor for several malignancies and 
cardiovascular diseases, and therefore knowledge about the prevalence and effects of smok-
ing in recipients of liver transplants is of utmost importance. However, studies about the role 
of smoking in recipients of liver transplants are scarce.
Besides the well-known effects of smoking on several malignancies, cardiovascular dis-
eases and lung disease, smoking also affects the digestive organs. Especially the role of 
smoking in IBD is remarkable. Smoking has opposite effects on CD and UC; smoking seems 
detrimental for CD, but beneficial for UC. In this introduction, we describe this remarkable, 
opposite role of smoking between CD and UC; in section 1.2 the detrimental effects of 
smoking on CD, in section 1.3 the beneficial effects of smoking on UC and in section 1.4 
some possible biological mechanisms involved in the effects of smoking in CD and UC. In 
addition, in section 1.5 we discuss smoking behaviour in OLT recipients and the effects of 
smoking after OLT.
Smoking and Crohn’s disease
CD patients are more likely to be smokers than their matched controls, making smoking a 
risk factor for developing CD. 2-5 In a meta-analysis of 1,679 CD patients, active smokers had 
an odds ratio (OR) of 1.76 (95% confidence interval (CI): 1.40-2.22) for developing CD.5 
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Not only active smoking, but also passive smoking may be a risk factor for developing CD. 
However, information about passive smoking as a risk factor for developing CD is scarce and 
inconclusive. Some studies showed that CD patients were more often exposed to tobacco 
smoke in childhood than controls.6,7 However, a meta-analysis showed no effect of passive 
smoking in childhood on CD, although a sub analysis based on effects of maternal smoking 
showed a positive association with CD (OR 1.3 (95% CI: 1.1–1.6)).8
In addition to the detrimental effect of smoking on the development, many studies showed 
that smoking was also unfavourable for the disease course of CD. Smoking CD patients had 
a higher need for hospitalizations,9 steroids,10-12 azathioprine 9-11,13 and surgery,9,14-16 and had 
earlier and/or more often recurrence after surgery than non-smokers.15,17-23 However, this 
detrimental effect of smoking on the course of CD was not confirmed by other studies.24-34 In 
contrast to the detrimental effect of smoking, two recent studies showed that smoking pro-
tected against relapse after azathioprine withdrawal.35,36 The literature on the effects of smok-
ing is not only ambiguous, the effects of smoking also seem to depend on gender,10,17,20,37 
and disease location and severity.18,38 The literature on the effect of smoking on the results of 
treatment with the anti-TNF-α antibody infliximab is also ambiguous. In a recent review two 
out of ten studies showed a higher response in non-smokers than in smokers, but the other 
eight studies showed no effect of smoking.39 In a study comparing a top-down and a step-
up strategy for the medical treatment of CD, smoking had no effect on the outcome either, 
including that of infliximab.40
Summarizing, active and maybe also passive smoking are risk factors for developing CD. 
Smoking may also be detrimental for the disease course of CD and may affect response on 
therapy, but literature is not conclusive on these matters.
Smoking and ulcerative colitis
Opposite to CD, UC patients are less likely to be smokers than controls, suggesting that 
smoking protects against developing UC. 3-5,41,42 In a meta-analysis of 2,459 UC patients ac-
tive smokers had a decreased risk for developing UC (OR 0.58 (95% CI: 0.45-0.75)), and 
former smokers had an increased risk (OR 1.79 (95% CI: 1.37-2.34)).5 The role of passive 
smoking for developing UC has also been studied. A protective effect of passive smoking in 
childhood was suggested,43 but this was not confirmed in a meta-analysis.8
Smoking may also be beneficial for the disease course of UC. Smokers had a lower need 
for hospitalizations,29,44 steroids 45 and a colectomy 16,26,45,46 than non-smokers. However, 
the positive effect of smoking on the colectomy rate was not always apparent in other co-
horts.25,27,44,47-49 Smoking cessation had detrimental effects on the course of UC, since pa-
tients who stopped smoking had a higher need for hospitalizations, steroids and azathioprine 
in the first year after stopping compared to continuing smokers.50 Finally, smoking protects 
against primary sclerosing cholangitis,51-53 an infamous extraintestinal disorder particularly 
associated with UC.
Summarizing, active smoking is protective and smoking cessation is a risk factor for de-
veloping UC. Smoking may also be detrimental for the disease course of UC, but as in CD, 
literature is not conclusive on this matter.
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Pathophysiology of  smoking in IBD
The cause of IBD is largely unknown, but it is thought to originate from a dysregulated im-
mune system influenced by genetics, environmental factors and commensal intestinal bac-
teria.54-56 It is not surprising that it is also unknown why smoking is detrimental for CD and 
beneficial for UC. Mechanisms that have been suggested to play a role are the Toll-like 
receptor-4-dependent pathway in macrophages,57 the heme-oxygenase-1 pathway (HO-1) 
58 and thrombogenic effects of tobacco on the intestinal microvasculature.59,60 HO-1 is the 
rate-limiting enzyme involved in the breakdown of heme, yielding the end-products biliver-
din, Fe2+ and carbon monoxide. Heme causes oxidative stress, while all three end-products 
have anti-oxidative, anti-apoptotic and anti-inflammatory properties. Induction of HO-1 was 
beneficial for the intestines in several animal models of oxidative injury and inflammation.
The understanding of the mechanism is complicated by the large number of components 
in cigarette smoke, of which nicotine and carbon monoxide are the most widely studied. 
Studies with nicotine showed that the detrimental effects of cigarette smoking on CD may be 
mediated by the binding of nicotine to the nicotinic acetylcholine receptor (nAChR) α7, which 
is an essential regulator of inflammation.61,62 In TNBS-induced colitis in rats the colon tissue 
was damaged more seriously when the nAChR-α7 expression was up-regulated by exposure 
to cigarette smoke.63 Another detrimental effect of nicotine was that it suppressed the clear-
ance of bacteria by macrophages.64 Clues for an association between UC and nicotine are 
the presence of nAChRs in colonic epithelium,65 and that nAChR-α5 knockout mice had a 
more severe experimental colitis than wild-type mice.66 Nicotine also has beneficial effects 
on epithelial mucus synthesis and gut motility, and it reduces the levels of pro-inflammatory 
cytokines and mucosal eicosanoids.46,67-69 Finally, several intervention studies suggested a 
beneficial effect of nicotine in UC patients with active disease.70,71 However, nicotine was not 
able to maintain remission of UC.72 Surprisingly, nicotine enemas were also beneficial for 
CD patients with colitis.73
The second widely studied component of cigarette smoke is carbon monoxide. In CD, car-
bon monoxide may amplify the impairment in vasodilation capacity of chronically inflamed 
micro-vessels, resulting in ischemia, and perpetuation of ulceration and fibrosis.74 Benefi-
cial effects of carbon monoxide are inhibition of the lipopolysaccharide-induced expres-
sion of pro-inflammatory cytokines (TNF-α, IL-1β and macrophage inflammatory protein-1β) 
and increase of the anti-inflammatory cytokine IL-10.75 Several interventions studies in mice 
showed beneficial effects of carbon monoxide; it ameliorated chronic intestinal inflammation 
in interleukin-10-deficient mice,76 and it inhibited the intestinal inflammation in a TNBS-
induced and DSS-induced colitis in mice with a decrease of TNF-a production and neutrophil 
infiltration into the intestinal mucosa.77,78 
Summarizing, it is still unknown which exact mechanisms of several suggested mechanisms 
in IBD are involved in mediating the effects of smoking, and which component(s) of cigarette 
smoke is/are involved. Nicotine and carbon monoxide are the most studied components, 
and both have detrimental as well as beneficial effects on intestinal inflammation.
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Smoking and liver transplantation
Only two studies, both from the United States, have studied the smoking behaviour in OLT 
recipients. DiMartini et al. prospectively studied the smoking behaviour in 33 patients trans-
planted for alcoholic liver disease. They found that more than 40% of patients with alcoholic 
liver disease were smoking after OLT, and that recipients resume smoking already at 3 
months post-OLT and increase consumption of cigarettes over time.79 Ehlers et al. retrospec-
tively studied the smoking behaviour in 202 recipients before and after OLT. They reported a 
lifetime history of smoking before OLT of 60% and an active smoker rate of 15% after OLT. 
Twenty percent of smokers who quitted before OLT relapsed after OLT.80 
The effects of smoking on the long-term course after liver transplantation have been stud-
ied more often. Smokers have an increased risk for malignancies after OLT,81-83 especially re-
cipients with alcoholic liver disease.84-86 Smoking OLT-recipients also had a higher incidence 
of cardiovascular events,87 and an increased risk of cardiovascular death and sepsis-related 
mortality compared with non-smokers.88 In a study on 263 OLT recipients smokers had a 
higher risk for developing vascular complications, especially arterial complications after liver 
transplantation.89 Finally, active smokers had a 92% higher rate of biliary complication rates 
compared with lifetime non-smokers in a study on 409 recipients.90
Summarizing, smoking is a risk factor for several complications and serious events after 
OLT, including for the most important causes of morbidity and mortality in these patient (ma-
lignancies and cardiovascular diseases), but literature on smoking behaviour in recipients is 
disappointingly scarce.
Outline of  the thesis
The general aim of this thesis is to explore the role of smoking in the inflammatory bowel 
diseases Crohn’s disease and ulcerative colitis, and the role of smoking in liver transplant 
recipients.
In chapter 2 we studied the smoking behaviour in patients with Crohn’s disease and ul-
cerative colitis. For this purpose we used a written questionnaire about active and passive 
exposure to cigarette smoke, and about cessation plans of active smokers. The aim was to 
identify possible differences in smoking behaviour between CD and UC patients.
In chapter 3 and 4 the effects of active and passive smoking on the disease courses of 
CD and UC are studied. In chapter 3, we studied IBD patients from a university hospital and 
in chapter 4 IBD patients from a general hospital. Smoking behaviour was defined by using 
the same questionnaire as in chapter 2. Data on the disease course was obtained through 
retrospective analysis of the patient records.
Chapter 5 reports on the interaction between smoking and genetic background in CD. It 
is likely that the development of CD is partly caused by an interaction between the several 
identified genetic variants and smoking, but studies investigating this interaction are scarce. 
In this study we aimed to explore whether there are differences in CD associated genetic vari-
ants between CD patients stratified for active smoking at diagnosis and for passive smoking 
in childhood.
Chapter 6 is a laboratory study on the effects of smoking on the expression of HO-1. 
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The HO-1 pathway could be one of the pathways involved in the beneficial effects of smok-
ing on UC. Induction of HO-1 was beneficial in several animal models of intestinal injury. 
Cigarette smoke is able to induce HO-1 in several human cells, but the effect of smoking 
on colonic HO-1 is unknown. Induction of colonic HO-1 by smoking could be beneficial for 
UC patients by protecting against development of UC and/or by ameliorating inflammation 
in established UC. We hypothesized that smoking increases the colonic HO-1 expression. 
For this purpose, we studied the effects of smoking on colonic HO-1 expression in vitro, in 
animals and in humans.
In chapter 7 we report about the smoking behaviour of liver transplant recipients before 
and after transplantation, and about the association of smoking with malignancies and car-
diovascular diseases after transplantation. One of the aims was to define groups at risk for 
resuming smoking after OLT. Smoking behaviour was defined by using a questionnaire about 
smoking habits at 4 time points before and after OLT. Data on the disease course after OLT 
were collected from the medical charts.
Finally the results of the studies as described in this thesis are summarized and future per-
spectives are given in chapter 8.
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Smoking is a remarkable risk factor in inflammatory bowel disease (IBD), with negative ef-
fects on Crohn’s disease (CD) and positive effects on ulcerative colitis (UC). This makes dif-
ferent changes in smoking behaviour after diagnosis between CD and UC likely. Changes in 
active smoking, cessation plans and passive smoking were studied in IBD patients.
Methods: 
820 IBD patients were sent a questionnaire on active and passive smoking, and cessation 
plans. A total of 675 (82%) patients (380 CD and 295 UC) responded.
Results: 
More ever smoking UC patients stopped smoking before diagnosis than CD patients (63% 
vs 22%; p<0.001), resulting in 30% former smokers at diagnosis in UC and 13% in CD 
(p<0.001). The smoking cessation rates at and after diagnosis are equal between CD and 
UC. Half of the CD patients stopped smoking after diagnosis leading to less present smokers 
in CD than in a control population (26% (95% confidence interval: 21.1%-29.9%) vs 33%). 
For both CD (22% vs 35%; p=0.044) and UC (24% vs 53%; p=0.024) continuing smokers 
after diagnosis were less often higher educated than quitters. Cessation plans (89%), passive 
smoking in childhood and present passive smoking were not different between CD and UC 
patients.
Conclusion: 
There are no differences in changes in smoking behaviour at and after diagnosis between 
CD and UC patients, suggesting a lack of knowledge in these patients about the link between 
their disease and smoking behaviour. However, CD patients seem less refractory to smoking 
cessation than the general population. Therefore it is worthwhile putting energy in helping 
CD patients stop smoking.
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Introduction
The chronic inflammatory bowel diseases (IBD) Crohn’s disease (CD) and ulcerative colitis 
(UC) are characterized by relapsing inflammation of the gastrointestinal tract. They share 
many clinical features, but there are also important differences, like the disease location and 
histological features. Another remarkable difference is the inverse effect of smoking on CD 
and UC. CD patients are more likely to be smokers than their matched controls, suggesting 
that smoking is a risk factor for development of CD.1-3 In contrast, UC patients are less likely 
to be smokers than controls, so smoking seems to protect against development of UC.2-4
In addition to the effect of smoking on the development of CD and UC, smoking also 
plays an important role on the disease course of both diseases. In CD, smokers more often 
experience flare-up episodes, have an increased need for steroids and immunosuppressants, 
and earlier recurrence after surgery.5-11 In UC, smokers experience less flare-up episodes, 
and need less often hospitalizations, steroids and surgery.11-15 The unfavourable effects of 
smoking on the disease course of CD patients make it very desirable for this category to stop 
smoking. Consequently, reviews have focussed on smoking cessation in CD,16,17 but to the 
best of our knowledge there are no studies about long term changes in smoking behaviour 
in CD patients after diagnosis. Furthermore, since smoking has beneficial effects in UC, 
smoking cessation in UC patients could lead to an increase in bowel complaints resulting in 
smoking relapse. Summarizing, smoking cessation is beneficial for CD patients, but could 
lead to unfavourable effects in UC patients. If CD and UC patients are aware of this link 
between their disease and smoking behaviour, different changes in smoking behaviour after 
diagnosis between CD and UC patients are likely.
As for active smoking, there could also be a role for passive smoking in IBD. Passive smok-
ing in childhood could be a risk factor for the development of IBD, but literature about this is 
scarce and inconclusive. Some studies showed that passive smoking in childhood was a risk 
factor for developing CD.18,19 A recent meta-analysis showed no effect of passive smoking in 
childhood on CD, although a subanalysis only based on effects of maternal smoking showed 
a positive association with CD (odds ratio 1.3 (95% confidence interval (CI): 1.1-1.6)).20 
In UC, a protective effect of passive smoking in childhood was suggested,21 but this could 
not be confirmed in a meta-analysis.20 Studies about present passive smoking in adult IBD 
patients are even scarcer, with one study that showed no difference in passive smoking habits 
between CD and UC patients, and between these patients and controls.22
The aim of this study was to extensively explore active smoking behaviour and passive 
smoking in CD and UC patients in a Dutch university hospital population. For active smoking 
behaviour we focussed on changes after diagnosis of IBD and cessation plans. For passive 
smoking we studied differences in passive smoking in childhood and present passive smok-
ing between CD and UC. We hypothesized that CD patients more often stop smoking and 
avoid passive smoking after diagnosis than UC patients, because CD patients become aware 
of the risks of smoking for their disease and/or UC patients experience more complaints after 
smoking cessation.  Secondly, we hypothesize that CD patients are more often exposed to 
passive smoking in childhood than UC patients.




All IBD patients who visited the outpatient department of our hospital between January 1995 
and October 2005, and had a known or incident diagnosis of CD or UC by defined criteria 
were included.23 A total of 820 alive IBD patients were identified and received a detailed 
questionnaire about smoking behaviour. A total of 675 patients responded to the question-
naire (82%) and were included in this study. Of these 675 patients we extensively described 
disease characteristics and behaviour before.15 Clinical characteristics including informa-
tion about active smoking were obtained through analysis of the medical charts. Detailed 
information about active and passive smoking behaviour was obtained through a written 
questionnaire. We compared the present smoking behaviour of CD and UC patients with 
a general, age adjusted Dutch population from the StatLine databank of the Dutch central 
agency for statistics (Statistics Netherlands;http://statline.cbs.nl). The methods used were dis-
cussed with the medical ethics committee and according to Dutch legislation there were no 
objections against it. A returned and refilled questionnaire was considered as an informed 
consent.
Characteristics and outcome variables
Patient characteristics recorded were gender, age at diagnosis (divided according to the 
Montreal-classification in below 16 years, between 17 and 40 years, and above 40 years),24 
and time of diagnosis. Time of diagnosis was the date of the first detection of inflamma-
tory abnormalities by radiological, endoscopic or peroperative examinations.23 The end of 
follow-up was October 2005, or the last date of clinical or outpatient visit for patients who 
were discharged or had withdrawn from outpatient control.
Questionnaire for smoking behaviour
The written and detailed questionnaire about smoking behaviour included questions about 
1) whether the patient had ever been smoking and if so, number of years smoked and, if a 
former smoker, months after cessation; 2) product smoked and average amount smoked per 
day; 3) the influence of the diagnosis of IBD on smoking behaviour; 4) plans for smoking 
cessation;25 5) willingness to participate in a free smoking cessation program; 6) passive 
smoking in childhood; 7) present passive smoking and 8) educational level. For studying 
passive smoking in childhood patients were asked whether he or she inhaled smoke from 
cigarette smokers at home being a child. For present passive smoking was asked how many 
times the patient was more than one hour in a room with smoking persons (every day, a few 
times a week, once a week or never).
Definitions of  active smoking behaviour
Smoking behaviour was determined at the time of diagnosis and at the time of completing 
the questionnaire (present smoking). At both time points patients were divided in smokers, 
former smokers and never smokers. For defining smoking behaviour at the time of diagnosis, 
we used the information about smoking behaviour and number of years smoked or number 
of months after smoking cessation, and the time of diagnosis from the medical chart. A 
smoker at diagnosis started smoking seven or more cigarettes per week at least six months 
before diagnosis, a former smoker quitted smoking at least six months before diagnosis and 
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a never smoker had never smoked until six months before diagnosis. The average amount 
smoked per day was adjusted by product smoked. Smoking 1 cigar was considered equal to 
4 cigarettes, as the average cigar contains 4 g of tobacco and a cigarette 1 g.26
Statistical analysis
Descriptive variables are presented as medians (interquartile range (IQR)) and categorical var-
iables as frequencies with percentages. The data were analyzed using the Statistical Package 
for the Social Sciences program version 12.0 (SPSS Inc., Chicago, Illinois, USA). Frequencies 
were compared with the chi-square test en medians with the Mann-Whitney test. Differences 
are considered significant when p<0.05. The 95% CI was calculated if appropriate.
Results
Patient characteristics and smoking behaviour at diagnosis
Of the 675 patients that responded to the questionnaire (82%), 380 (56%) were known with 
CD and 295 (44%) with UC (table 1). CD patients were younger at diagnosis, more often 
female and had a longer follow-up than UC patients. CD patients were more often smokers 
and UC patients were more often both former and never smokers at diagnosis. In a previous 
study we already confirmed the difference in active smoking behaviour at diagnosis between 
CD and UC patients, and between these patients and the general population, with 52% 
(95%CI: 47.1%-57.2%) smokers in CD, 41% smokers in the general population and 28% 
(95%CI: 22.7%-32.9%) smokers in UC.15
To study changes in active smoking behaviour after diagnosis in CD and UC, we explored 
the influence of the diagnosis on the smoking behaviour and the present smoking behaviour 
(table 2). We hypothesized that when CD patients are aware of the risks of smoking for their 
disease and/or UC patients experience more complaints during smoking cessation, than 
after diagnosis CD patients more often have stopped smoking than UC patients.
First, ever smokers (smokers and former smokers) at diagnosis were asked about the 
influence of the diagnosis of IBD on their smoking behaviour. UC patients more often had 
already stopped smoking before the diagnosis than CD patient. Smoking cessation rate at 
diagnosis was not different between CD and UC patients, although CD patients more often 
reduced smoking after being diagnosed with the disease. Relatively more CD patients did 
not change their smoke behaviour at diagnosis than UC patients.
Next, present active smoking was studied. Presently CD patients are still more often smok-
ers and UC patients are more often never smokers. Furthermore, the number of cigarettes 
smoked per day is higher in present CD smokers than UC smokers. We compared the 
number of smokers with an age adjusted control population, in which 35% were smokers in 
2006. In both CD (26% (95%CI: 21.1%-29.9%)) and UC (10% (95%CI: 6.4%-13.3%)) the 
number of present smokers is lower. Considering the higher number of females in CD, we 
also adjusted the smoking behaviour of the controls to gender. This leads to 33% smokers, 
which is still higher than in CD patients.
Active smoking after diagnosis and influence of  the diagnosis on 
smoking behaviour
Smoking behaviour in IBD
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Table 1 Characteristics of  the respondents.
Characteristic: n (%) CD (n=380) UC (n=295) p-value
Gender: female 241 (63.4) 139 (47.1) <0.001
Age at diagnosis:
  median (yrs) (IQR) 
  below 16 yrs: n (%)
  between 17 and 40 yrs: n (%)
































Follow-up: median(yrs) (IQR) 9.4 (4.9-19.0) 8.5 (4.1-14.6) 0.008
Education:    












Smoking behaviour at diagnosis:
  smoker
  former smoker











CD: Crohn’s disease; IQR: interquartile range; UC: ulcerative colitis.
Table 2 Influence of  diagnosis on smoking behaviour in ever smoking CD and UC patients, and present 
smoking behaviour in all patients.
Characteristic: n (%) CD (n=380) UC (n=295) p-value
Influence of  diagnosis on smoking:
  already stopped 
  stopped then
  started again
  started smoking less
  started smoking more





















  former smoker










Cigarettes per day: median (IQR)
  present active smokers







CD: Crohn’s disease; IQR: interquartile range; UC: ulcerative colitis.
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Finally, to study differences in smoking cessation rates after diagnosis between CD and 
UC patients, we analyzed whether smokers at diagnosis were presently still smoking. Here to 
we excluded the smokers at diagnosis who stopped smoking within one year after diagnosis, 
because of our relatively rough measures of smoking behaviour at diagnosis. After this ex-
clusion, 91 of the 179 (51%) CD patients and 38 of the 63 (60%) UC patients had stopped 
smoking after diagnosis. This difference is not significant (p=0.195). In addition, differences 
between the continuing smokers and the smokers that stopped smoking after diagnosis were 
studied. For CD, the continuing smokers were more often lower (34% vs 21%; p=0.047) 
and less often higher (22% vs 35%; p=0.044) educated than quitters, and smoked less 
often cigarettes (53% vs 78%; p=0.001) and cigars (1% vs 8%; p=0.034) than quitters. For 
UC, the continuing smokers were less often higher educated (24% vs 53%; p=0.024) than 
quitters and smoked fewer cigarettes per day (median (IQR): 10.0 (5.0-12.5) vs 12.5 (9.3-
20.0); p=0.005) than quitters. For both diseases no differences were found for gender, age 
at diagnosis, onset of disease and passive smoking in childhood.
Summarizing, UC patients more often stopped smoking before diagnosis and the cessation 
rate at diagnosis is similar. In contrast to our hypothesis, CD patients did not stop smoking 
more often after diagnosis than UC patients. However, still half of the CD patients have man-
aged smoking cessation after diagnosis leading to a lower number of present smokers in 
CD than in a control population. In both CD and UC, a higher education is associated with 
smoking cessation after diagnosis.
Smoking cessation plans
To explore our hypothesis that CD patients are more willing to quit smoking compared to UC 
patients, we studied the smoking cessation plans and willingness to participate in a smoking 
cessation program for present smoking CD and UC patients (table 3). We could not confirm 
our hypothesis that there are differences between CD and UC patients in smoking cessation 
plans and willingness to join a group course for smoke cessation. However, for both diseases 
about 90% had the intention to stop smoking, although less than 30% wanted to join a free 
course for smoking cessation.
Table 3. Smoking cessation plans and intention to join a group course for cessation in smoking CD and 
UC patients.
Characteristic: n (%) CD (n=97) UC (n=29) p-value
Cessation plan:
  within 6 months
















Group course for cessation:
  yes
  maybe











CD: Crohn’s disease; UC: ulcerative colitis.
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Passive smoking in childhood
To study the relation between passive smoking and the development of IBD, we explored 
differences in passive smoking in childhood between CD and UC. We studied this in all pa-
tients, in patients with onset of disease before 40 years and with onset of disease before 16 
years (Fig. 1). In all these groups passive smoking in childhood between CD and UC patients 
did not differ significantly.
Present passive smoking behaviour in non-smokers
Finally, we studied differences in present passive smoking between CD and UC. We studied this 
in present non-smokers (former and never smokers) to exclude a confounding effect of present 
active smoking. The present passive smoking in non-smoking CD and UC patients is shown 












    yes        no    unknown          yes        no     unknown          yes        no    unknown
All patients (CD: n=355;
UC: n=276)
Onset of disease <40
years (CD: n=263; UC:
n=198)
Onset of disease <16





Figure 1. Passive smoking in childhood in Crohn’s disease (CD) and ulcerative colitis (UC) patients, with 
no significant differences between CD and UC. Numbers are shown for all patients, for patients with an 












        daily       few times/week   once/week   rarely if ever                      daily          few times/week    once/week     rarely if ever
                                                                                                   Former and never smokers (CD: n=283; UC: n=266)                                                                                                    Never smokers (CD: n=127; UC: n=125)
Crohn's disease
ulcerative colitis
Figure 2 Figure 2. Present passive smoking in Crohn’s disease (CD) and ulcerative colitis (UC), with no significant 
differences between CD and UC. Numbers are shown for present non-smokers (former and never smokers) 
and for present never smokers.
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alone. In disagreement with our hypothesis that CD patients are aware of the risks of smoking 
for their disease and therefore more often avoid passive exposure to smoke than UC patients, 
we could not show significant differences in present passive smoking between CD and UC.
Discussion
Smoking is a remarkable and well established risk factor in IBD, with negative effects on CD 
and positive effects on UC. The inverse effects of smoking on CD and UC makes differences 
in changes in smoking behaviour after diagnosis between CD and UC likely, but hitherto no 
such information was available. Therefore, we extensively studied changes in active smok-
ing, cessation plans and passive smoking in CD and UC patients in a large, Dutch university 
hospital population. The smoking cessation rate before diagnosis is higher in UC, but ces-
sation rates at diagnosis and after diagnosis are equal between CD and UC. Half of the 
CD patients have managed smoking cessation after diagnosis leading to a lower number 
of present smokers in CD than in a control population. Cessation plans and willingness to 
join a cessation course are not different between CD and UC patients. Passive smoking in 
childhood and present passive smoking were studied, and both were not different between 
CD and UC.
In a previous analysis of this IBD population we already confirmed the difference in active 
smoking behaviour at diagnosis between CD and UC patients, and between these patients 
and a control population, with 52% (95%CI: 47%-57%) smokers in CD, 41% smokers in the 
controls and 28% (95%CI: 23%-33%) smokers in UC.15 In the present analysis, it was shown 
that in ever smoking IBD patients, 63% of ever smoking UC patients stopped smoking before 
diagnosis compared to only 22% of CD patients, resulting in 30% former smoking patients 
in UC and 13% in CD at diagnosis. These numbers of former smokers are comparable with 
the numbers Aldhouse et al. reported, although they defined former smokers as those who 
had stopped smoking one year or more before diagnosis instead of the six months in our 
study.27,28 This striking difference in former smokers between CD and UC is supportive for a 
causal relationship between smoking cessation and developing UC.
We hypothesized that CD patients more often stop smoking after diagnosis and avoid 
passive smoking after diagnosis than UC patients, because CD patients become aware of 
the risks of smoking for their disease and/or UC patients experience more complaints after 
smoking cessation. However, our results are in contradiction with this. First, more CD pa-
tients reported no influence of the diagnosis on smoking behaviour than UC patients (43% 
vs 22%) and smoking cessation at diagnosis was not different between CD and UC patients 
(14% vs 9%). Next, CD patients did not more often stop their smoking after diagnosis than 
UC patients (51% vs 60%) and CD patients did not more often avoid passive exposure to 
cigarette smoke. Finally, the present cessation plans are also not different between CD and 
UC patients; in both diseases about 35% have the intention to stop within six months. Not 
only are there no clear differences in changes in smoking behaviour between CD and UC 
patients, presently CD patients smoke more cigarettes per day than UC patients (12 vs 10).
Fortunately, there are also some positive findings in CD patients. First, CD patients more 
often reduced smoking at diagnosis than UC patients (18% vs 3%). Next, half of the CD pa-
tients have managed smoking cessation after diagnosis leading to a lower number of present 
Smoking behaviour in IBD
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smokers in CD than in the controls. Finally, in both diseases only 11% of the patients have no 
intention to stop smoking. This number is favourable compared to that in a group of 6260 
healthy smokers from Australia, Canada, USA and UK in which 26% had no intention to stop 
smoking.29 Therefore, both the intention to stop and the cessation rate in CD patients is better 
than in the general population. Thus, CD patients are less refractory to smoking cessation 
than the general population and therefore it is absolutely worthwhile to put energy in helping 
CD patients stop smoking. This is more or less in line with a previous study, that did not find 
evidence that smoking CD patients were overly refractory to smoking cessation.30 Reviews 
that could be helpful in assisting CD patients with smoking cessation are available.16,17 Fur-
thermore, it is important to keep in mind that CD patients could be less aware of the risks of 
smoking on their disease than we think, since studies showed an unawareness in CD patients 
of the association between smoking and their disease.31,32 Another issue to keep in mind is 
that level of education plays an important role in smoking cessation in the general popula-
tion.33,34 We confirmed this in both CD and UC patients, since patients who succeeded in 
smoking cessation after diagnosis more often had completed higher education. Cosnes et al. 
showed that high socioeconomic status was a predictor of smoking cessation for more than 
one year in their intervention study.35
In addition to changes in active smoking behaviour and present passive smoking, we also 
studied differences in passive smoking in childhood between CD and UC patients. Some 
studies have suggested that passive smoking in childhood could also have effects on the 
development of CD and UC,18,19,21 but a recent meta-analysis showed no differences in 
passive smoking in childhood between both CD and UC, and controls.20 Our findings of an 
equal rate in passive smoking in childhood between CD and UC patients are in line with this, 
although we did not include a control population. However, the effects of passive smoking 
in childhood could be dose-dependent 20,36,37 and therefore more studies are needed that 
analyze the effects of different levels of passive smoking in childhood on IBD.
It is important to note limitations of our study. Using a questionnaire may lead to selection 
bias, because it takes more time for smokers and/or former smokers to fill in the survey and 
they could be less willing to respond. However, the high response-rate to our questionnaire 
(82%) makes this unlikely. Asking about smoking behaviour in the past and the influence of 
the diagnosis of the disease on smoking behaviour could introduce a recall bias. The data 
on passive smoking in childhood was not confirmed by asking the parents of the patients. 
However, using a written questionnaire gives patients time to ask their parents about it.
In conclusion, we extensively studied changes in active smoking, cessation plans and pas-
sive smoking in CD and UC patients. The smoking cessation rate before diagnosis is higher 
in UC, but cessation rates at and after diagnosis are equal among CD and UC patients. In 
addition, there are no indications that CD patients avoid passive exposure to smoke more 
often. These findings suggest a lack of knowledge in CD and UC patients about the link 
between their disease and smoking behaviour, although our questionnaire did not address 
this knowledge in particular. However, half of the CD patients have managed smoking ces-
sation after diagnosis leading to a lower number of present smokers in CD than in a control 
population, and many CD patients have cessation plans. So, CD patients are less refractory 
to smoking cessation than the general population and therefore it is worthwhile to put energy 
in helping CD patients stop smoking. In both CD and UC, a higher education is associated 
with smoking cessation after diagnosis. Finally, passive smoking in childhood was not differ-
ent between CD and UC, but further research on this matter is needed.
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Smoking is a remarkable risk factor for inflammatory bowel disease (IBD), aggravating 
Crohn’s disease (CD) while having beneficial effects on ulcerative colitis (UC). We studied 
the effects of active and passive smoking in Dutch IBD patients.
Methods: 
A questionnaire focussing on cigarette smoke exposure was sent to 820 IBD patients. Re-
turned questionnaires were incorporated into a retrospective chart review, containing details 
about disease behaviour and received therapy.
Results: 
675 IBD patients (380 (56%) CD and 295 (44%) UC) responded. At diagnosis there were 
52% smokers in CD, 41% in the general population and 28% in UC. The number of present 
smokers in CD is lower than in the general population (26% vs. 35%). No detrimental effects 
of active smoking on CD were observed, but passive smokers needed more frequently im-
munosuppressants and infliximab than non-passive smokers. Active smoking had beneficial 
effects on UC, indicated by reduced rates of colectomy, primary sclerosing cholangitis and 
backwash-ileitis in active smokers compared to never smokers, and higher daily cigarette-
dose correlated with less extensive colitis and lower need for therapy. Furthermore, smoking 
cessation after diagnosis was detrimental for UC patients, indicated by increased needs for 
steroids and hospitalizations for patients that stopped smoking after compared to before the 
diagnosis.
Conclusion: 
Active smoking is a risk factor for CD, but does not affect the outcome; passive smoking is 
detrimental for the outcome of CD patients. In UC, active smoking shows dose-dependent 
beneficial effects. Our data suggest that passive smoking is a novel risk factor for CD. 
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Introduction
Chronic inflammatory bowel diseases (IBD), comprising Crohn’s disease (CD) and ulcerative 
colitis (UC), are characterized by chronic relapsing inflammation of the gastrointestinal tract. 
They share many clinical features, but there are also important differences, like the disease 
location and histological features. Another remarkable difference is the effect of smoking on 
CD and UC. Several studies have shown that patients with UC are less likely to be smokers 
than controls or patients with CD.1 In contrast, CD patients are more likely to be smokers 
than their matched controls.2-5 So smoking seems to be a contributing factor for the develop-
ment of CD, while it protects against the development of UC.
Besides the association between smoking and the prevalence of IBD, several studies 
showed an unfavourable effect of smoking on the disease course of CD and a beneficial 
effect on that of UC. Smoking in CD was associated with more flare-up episodes,6 more 
complications,7 increased need for steroids6 and immunosuppressants6,8,9 and earlier recur-
rence after surgery.10-12 However, other studies did not confirm these findings.13-20 In contrast 
to the unfavourable effect of smoking in CD, in UC smoking was associated with less flare-up 
episodes,21 lower number of hospitalizations,14-16,18,21 and decreased need for oral steroids22 
and surgery.18,23 However, the positive effect of smoking on colectomy rate was not shown 
in other cohorts.14,21,24,25 So studies about the role of smoking on the disease course of CD 
as well as UC give conflicting results, and effects of smoking seem to depend on gender,8,26 
disease location and severity.27 Furthermore, like the effects of active smoking on IBD, pas-
sive smoking may also affect the course of IBD. However, very little is known on the effect of 
passive smoking on the disease course of IBD. 
The aim of this study was to analyze the relationship between smoking (active and passive 
smoking and smoking cessation) and the course and behaviour of CD and UC over a mean 
time frame of 13 years in a Dutch IBD cohort at a university hospital. We hypothesized that 
1) both active and passive smoking are detrimental for the disease course of CD and 2) both 
active and passive smoking are beneficial for the disease course of UC.
Methods 
Patients
IBD patients who visited the outpatient department of our hospital between January 1995 
and October 2005 and had a confirmed diagnosis of CD or UC by endoscopic, radiologic 
or pathologic examinations28 were included. Patients are seen at a regular basis and more 
often if needed at our outpatient department. Patients with indeterminate colitis or a concom-
itant liver transplantation were excluded. A total of 820 IBD patients alive were identified. 
Detailed information about smoking behaviour was obtained through a written question-
naire. Smoking behaviour at diagnosis (median year of diagnosis was 1995) of CD and UC 
patients were compared with 1995-records of a general, age adjusted Dutch population of 
the StatLine databank of the Dutch central agency for statistics (Statistics Netherlands;http://
statline.cbs.nl). Clinical characteristics and the outcome variables were obtained through 
retrospective analysis of the medical charts. The methods used were discussed with the medi-
cal ethics committee. According to Dutch legislation there were no objections against the 
methods used. A returned questionnaire was considered as an informed consent.
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Questionnaire for smoking behaviour
All patients received a detailed questionnaire about smoking behaviour. This included ques-
tions about 1) whether the patient had ever been smoking and if so, number of years smoked 
and, if a former smoker, months after cessation; 2) product smoked and average amount 
smoked per day; 3) the relation between diagnosis and smoking behaviour; 4) passive smok-
ing at present (every day, a few times a week, once a week or never/seldom more than one 
hour a day in the same room with smoking persons); 5) educational level and 6) family his-
tory of IBD. 
Definitions of  smoking behaviour
Smoking behaviour was determined at the time of diagnosis and at the time of completing the 
questionnaire (present smoking), and patients were divided in smokers, former smokers and 
never smokers. A smoker at diagnosis started smoking seven or more cigarettes per week at 
least six months before diagnosis, a former smoker quitted smoking at least six months before 
diagnosis and a never smoker had never smoked until six months before diagnosis.    
For studying the relation between smoking and disease course, patients were divided in: 1) 
smokers after diagnosis (smoker at diagnosis who did not stop smoking within one year after 
diagnosis, or former smoker at diagnosis who restarted smoking within one year after diag-
nosis, or never smoker at diagnosis who smoked within one year after diagnosis), 2) quitters 
after diagnosis (smoker at diagnosis who stopped smoking within one year after diagnosis), 3) 
quitters before diagnosis (former smoker at diagnosis who did not restart smoking within one 
year) and 4) never smokers after diagnosis (never smoked until one year after diagnosis). 
The level of smoke exposure was analyzed in smokers after diagnosis by dividing the pa-
tients in three groups according to the number of cigarettes smoked per day (<10, 10-15, 
>15 per day). Smoking of one cigar was considered equal to four cigarettes, as the average 
cigar contains four grams of tobacco and a cigarette one gram.29 For studying the relation 
between passive smoking and disease course, never smokers were divided in two groups: 1) 
passive smokers (daily, few times a week or once a week exposed to a smoking environment) 
and 2) non-passive smokers (rarely or never exposed).
Clinical characteristics and outcome variables
Patient characteristics recorded were gender, age at diagnosis (divided according to the Vien-
na-classification in early age onset (< 40 years) and late onset disease (> 40 years)),30 time 
of diagnosis and type of disease (CD or UC). The time of diagnosis was defined as the date 
of the first detection of inflammatory abnormalities by radiological, endoscopic or peropera-
tive examinations. For CD, disease behaviour and location were determined according to the 
Vienna-classification.30 Behaviour was determined at diagnosis and during follow-up. For UC, 
location was defined as proctitis, left-sided colitis (not extending beyond the splenic flexure) 
and pancolitis with or without backwash-ileitis, defined as mucosal inflammation of the termi-
nal ileum as a continuation of colonic involvement, without histological features of CD. We 
determined the location at diagnosis and the maximal extend during follow-up. Extraintestinal 
manifestations (EIM), including primary sclerosing cholangitis (PSC), were noted.
We recorded the use of 5-aminosalicylates (5-ASA) (oral and topical), steroids (oral, topi-
cal and iv), azathioprine or 6-mercaptopurine, methotrexate, cyclosporine and infliximab 
at any time during follow-up. For infliximab we recorded the indication (luminal or fistuliz-
ing disease) and response to induction or maintenance therapy according to a previously 
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reported three point scale.31 Surgery for CD was defined as any intra-abdominal surgical 
procedure for treatment of CD or its complications, incision and drainage of a perianal 
abscess, and surgical treatment of perianal fistula. For UC surgery was defined as a (sub)
total colectomy. Furthermore, construction of a pouch and development of pouchitis were 
recorded. Hospitalizations were defined as any admission for a flare-up of the disease, for a 
surgical procedure as outlined above or for non-surgical treatment of a complication due to 
stricturing or penetrating disease behaviour. Hospitalizations for scheduled infliximab infu-
sions were excluded. 
All events were recorded till the end of follow-up, October 2005. The last date of clinical 
or outpatient control visit was considered the end of follow-up for patients who were dis-
charged or had withdrawn from outpatient control. For UC patients after a colectomy and 
without development of pouchitis, the date of colectomy was the end of follow-up.
Statistical analysis
Descriptive variables are presented as medians (interquartile range (IQR)) and categori-
cal variables as frequencies with percentages. The data were analyzed using the Statistical 
Package for the Social Sciences program version 12.0 (SPSS Inc., Chicago, Illinois, USA). 
Frequencies were compared with the chi-square test and means between two groups with 
the Mann-Whitney test and between three or more groups with the Kruskal-Wallis test. Dif-
ferences are considered significant when p ≤ 0.05. All patient characteristics that showed 
a p-value ≤ 0.10 in univariate analysis were included in the Cox-regression analysis for 
multivariate analysis with follow-up as time variable. The odds ratios (OR) and the 95% 
confidence intervals (95% CI) were calculated if appropriate.
Results
Patients characteristics and smoking behaviour
From the 820 patients, 675 patients responded to the questionnaire (82%), with 380 (56%) 
CD and 295 (44%) UC patients. Of the responders, demographic characteristics, smoking 
behaviour (at diagnosis and present), frequency of EIM, Vienna-classification for CD, and lo-
cation at diagnosis and maximal location for UC are shown in Table 1. CD patients were more 
often female and younger at diagnosis, and had a longer follow-up than UC patients. At diag-
nosis CD patients were more often smokers and UC patients were more often former smoker 
as well as never smokers. At the median time point of diagnosis (1995) 41% were smokers in 
the control population. For CD this gives an OR of 1.27 (95%CI: 1.15-1.40) and for UC 0.68 
(95%CI: 0.55-0.80) for being a smoker at diagnosis. At present, CD patients are still more 
often smokers than UC patients and UC patients are more often never smokers. However, the 
number of present active smokers in CD (26% (95%CI: 21.1%-29.9%)) was lower compared 
to the control population, in which 35% were smokers in 2006. This gives for CD an OR of 
0.74 (95%CI: 0.60-0.85) and for UC 0.29 (95%CI: 0.18-0.38) for being a present smoker. 
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Table 1 Characteristics of  the respondents with CD and UC
Characteristic: n (%) CD (n=380) UC (n=295) p-value
Gender: female 241 (63.4) 139 (47.1) <0.001
Age at diagnosis:
  median (yrs) (IQR) 
  early onset: n (%)
  late onset: n  (%)
26.7 (20.6-39.7)
286 (75.3)
94 (24.7)  
32.4 (23.9-41.7) 
210 (71.2)




Follow-up: median (yrs) (IQR) 9.4 (4.9-19.0) 8.5 (4.1-14.6) 0.008
Lost to follow-up 32 (8.4) 44 (14.9)
Education:    
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  former smoker
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EIM 62 (16.3) 39/292 (13.4) ns
PSC 5 (1.3) 21 (7.1)   <0.001
Location CD:
  terminal ileum
  colon
  ileocolon





































*: B1= non-stricturing, non-penetrating; B2= stricturing; B3= penetrating.
CD: Crohn’s disease; EIM: extraintestinal manifestations; IQR: interquartile range; 
PSC: primary sclerosing cholangitis; UC: ulcerative colitis. 
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Patient characteristics according to smoking behaviour at diagnosis 
In CD, never smokers were the youngest at diagnosis, followed by smokers, whereas former 
smokers were the oldest at diagnosis (22.4 (IQR 16.7-30.9) vs. 28.3 (IQR 22.0-37.9) vs. 
43.4 (IQR 31.4-54.3) years; p<0.001). Disease behaviour at diagnosis was similar for 
smokers, former smokers and never smokers. In UC, never smokers were the youngest at 
diagnosis, followed by smokers, whereas former smokers were the oldest at diagnosis (24.9 
(IQR 20.3-32.8) vs. 32.1 (IQR 25.4-38.4) vs. 42.4 (IQR 34.6-52.9) years; p<0.001). 
Smokers had a similar disease localisation at diagnosis as former and never smokers, but 
never smokers presented more often with a pancolitis (27% vs. 15%; p=0.048) and less 
often with a left-sided colitis at diagnosis (29% vs. 48%; p=0.006) than former smokers. 
 
Disease outcome in Crohn’s disease
Active smoking
The relation between smoking behaviour and outcome variables in CD is depicted in Table 
2. Smoking CD patients used more often oral 5-ASA, but despite the hypothesized negative 
effect of smoking, there were no differences between smokers and never smokers for the other 
outcome variables. We observed no differences in outcome between quitters after and before 
diagnosis, except that ileocolonic disease was more frequent in quitters after diagnosis. Quit-
ters after diagnosis less often had a change in disease behaviour than smokers. Quitters before 
diagnosis had less hospitalizations, surgery and ileocolonic disease, and a more beneficial 
disease behaviour than smokers. However, the follow-up of both quitters after and before di-
agnosis is shorter than for smokers. Less EIM were experienced by smokers than never smokers 
and by quitters before diagnosis than quitters after diagnosis. 
So no main differences between the outcome of smokers and never smokers were shown. It is 
possible that these findings are biased by our definition of smokers after diagnosis (no smoking 
cessation within one year after diagnosis), because a patient that stopped smoking two years 
after diagnosis is nevertheless called a smoker after diagnosis. Some of our so-called smokers 
after diagnosis probably have stopped smoking more than a year after diagnosis, since our 
data show a drastic decline in active smokers between time of diagnosis and end of follow-up 
(from 52% to 26%). Therefore, we composed a subgroup of patients that smoked during the 
complete follow-up and compared them with the never smokers. This subgroup of smokers 
received more often iv steroids than never smokers (16% vs. 6%; p=0.010), but there were no 
differences for the other outcome variables. In addition, no differences in outcome between 
smokers and never smokers were found in female CD patients, including female CD patients 
with ileal disease. Furthermore, the outcome of treatment of luminal or fistulizing disease with 
infliximab did not differ between smokers, quitters and never smokers (data not shown).
In CD no dose-effect of smoking in smokers after diagnosis could be established on one of 
the outcome variables (data not shown). 
Passive smoking 
Since several studies have shown an unfavourable effect of active smoking on the course of 
CD, we also studied the effects of passive smoking. We divided never smoking CD patients 
in passive and non-passive smokers. Even with a shorter follow-up (median 7 years vs. 13 
years; p=0.002), passive smokers (n=56) needed more immunosuppressants (68% vs. 49%; 
p=0.039) and infliximab (29% vs. 11%; p=0.013) compared to non-passive smokers (n=65). 
No effect of passive smoking was observed for the other outcome variables (data not shown).
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Table 2. Outcome variables for Crohn’s disease according to smoking behaviour after diagnosis
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IS¶ 100 (60.2) 15 (45.5) 25 (52.1)  74 (56.5)
Infliximab 34 (20.5) 4 (12.1) 9 (18.8) 25 (19.1) 
EIM 21 (12.7) 8 (24.2) 4 (8.3)# 0.048
29 (22.1)*0.030
†0.035
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  B1 at diagnosis to
  B2 or B3 
69/113 (61.1) 7/21 (33.3) )*0.019  11/34 (32.4) )*0.003 43/90 (47.8) )*0.059   
*: p ≤ 0.05 vs smokers; #: p ≤ 0.05 vs quitters after diagnosis; †: p ≤ 0.05 vs quitters before diagnosis. 
¶: Azathioprine, 6-mercaptopurine and/or methotrexate.
§: B1= non-stricturing, non-penetrating; B2= stricturing; B3= penetrating.
5-ASA: 5-aminosalicylates; EIM: extraintestinal manifestations; IQR: interquartile range; IS: immunosup-
pressants; PSC: primary sclerosing cholangitis.
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Disease outcome in ulcerative colitis
Active smoking
The relation between smoking behaviour and disease outcome variables in UC is depicted 
in Table 3. These data show a beneficial relation between active smoking and outcome in 
UC, except for pouchitis. Even with a longer follow-up, smoking UC patients had a lower 
colectomy rate, less PSC, and less backwash-ileitis than UC patients who never smoked. The 
development of pouchitis was not significantly different between smokers and never smokers, 
but patients who quitted smoking before diagnosis had less pouchitis than smokers. Quitters 
before diagnosis had fewer hospitalizations and needed less oral steroids than quitters after 
diagnosis. Quitters before diagnosis more often had left-sided colitis and less often pancolitis 
during follow-up than never smokers.
Cigarette-dose 
A dose-dependent beneficial effect of smoking on disease outcome variables of UC was 
observed in smokers after diagnosis (Figure 1). Heavy smokers (>15 cigarettes/day) had less 
extensive disease (75% vs. 100%; p=0.023), received less oral (56% vs. 88%; p=0.032) 
and iv steroids (0% vs. 35%; p=0.006), used less immunosuppressants (15% vs. 47%; 
p=0.033), and had less hospitalizations (26% vs. 59%; p=0.048) than light smokers (<10 
cigarettes/day).
Passive smoking 
We divided never smoking UC patients in passive and non-passive smokers. In contrast to 
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Figure 1. Daily dose-effect 
of  active smoking in ulcera-
tive colitis
*: p-value < 0.05; #: p-value 
< 0.01; 
†: inflammation above 
proctum; ¶: Azathioprine, 
6-mercaptopurine and/or 
methotrexate; 
§: hospitalizations once or 
more.
IS: immunosuppressants.
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Table 3 Outcome variables for ulcerative colitis according to smoking behaviour after diagnosis









  median (yrs) (IQR) 
11.2 (7.1-18.5) 4.9 (3.8-13.7)*0.007 6.5 (2.8-12.3)*<0.001 9.0 (4.1-15.3)*0.035
†0.037
Hospitalizations:
  at least one












Colectomy 7 (12.1) 5 (20.8) 13 (15.1) 35 (27.8)*0.018 
†0.031
Pouch 5 (8.6) 0 5 (6.0) 15 (12.0) 
Pouchitis 5/5 (100) 0 1/5 (20.0)*0.010 9/15 (60.0)




































IS¶ 16 (27.6) 10 (41.7) 28 (32.6)  48 (38.1)
Cyclosporine 3 (5.2) 1 (4.2) 2 (2.3) 3 (2.4) 
EIM 5/57 (8.8) 2 (8.3) 9/85 (10.6) 23/125 (18.4)




  left-sided 




14 (25.9)  
0
8 (33.3)
11 (45.8)  












  left-sided 



















  proctitis/ left-sided to  
  pancolitis/ backwash
12/40 (30.0) 7/19 (36.8) 19/72 (26.4) 36/87(41.4)†0.048
*: p ≤ 0.05 vs. smokers; #: p ≤ 0.05 vs. quitters after diagnosis; †: p ≤ 0.05 vs. quitters before diagnosis.
¶: Azathioprine, 6-mercaptopurine and/or methotrexate.
5-ASA: 5-aminosalicylates; EIM: extraintestinal manifestations; IQR: interquartile range; IS: immunosuppres-
sants; PSC: primary sclerosing cholangitis.
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(100% vs. 44%; p=0.038) and backwash-ileitis (16% vs. 4%; p=0.023) than non-passive 
smokers (n=75). No effect of passive smoking was observed on the need for medication, 
surgery, and hospitalizations (data not shown). 
Multivariate analysis 
In CD multivariate analysis with Cox-regression analysis identified only quitting smoking be-
fore diagnosis as a protective factor for at least one hospitalization (OR 0.64 (95%CI 0.43-
0.95)). No independent factors were shown for at least two hospitalizations. For surgery, quit-
ting smoking before diagnosis was not an independent factor whereas late onset of disease 
(OR 0.65 (95%CI 0.47-0.91)) and a continuous B1 disease behaviour during follow-up (OR 
0.13 (95%CI 0.06-0.30)) were protective factors for at least one surgical procedure. 
In UC multivariate analysis identified smoking after diagnosis as a protective factor for 
colectomy (OR 0.27 (95%CI 0.11-0.67)) whereas pancolitis at diagnosis (OR 3.18 (95%CI 
1.85-5.48)) was a risk factor. Never smoking was a risk factor for the development of PSC 
in UC patients (OR 4.32 (95%CI 1.52-12.25)). Proctitis (OR 0.09 (95%CI 0.02-0.39)) and 
left-sided colitis at diagnosis (OR 0.35 (95%CI 0.13-0.93)) were associated with a lower 
risk for PSC.
Discussion
This study shows that active smoking has a dose-dependent beneficial effect on UC and 
smoking cessation after diagnosis was detrimental for UC patients. Remarkably, we did not 
observe a detrimental effect of active smoking on the disease course of CD, while our results 
suggest a detrimental role for passive smoking in CD. The differences in active smoking 
behaviour at diagnosis between CD patients, the general population and UC patients as 
observed by previous investigators were confirmed, with 52% smokers in CD, 41% in the 
general population and 28% in UC. Fortunately, many of the CD patients stop smoking after 
diagnosis, as the number of present smokers in CD is lower than in the general population 
(26% vs. 35%). 
In contrast to the detrimental role of smoking on CD in previous studies, our study with a 
mean follow-up of 13 years showed that smokers had a later onset of disease than never 
smokers and also experienced fewer extraintestinal manifestations. The relation between 
never smoking and early disease onset has been shown before32 and it advocates for a more 
prominent role of other predisposing factors in never smokers, in particular genetic predis-
position. Quitters before diagnosis had less hospitalizations and surgery than smokers, but 
we think this is mainly caused by the longer follow-up of smokers. Studies from Israel,18,19 
Spain15,16 and Norway14 showed no detrimental effect of smoking on the course of CD either. 
In the studies from Spain and Israel the smoking behaviour of CD patients did not differ 
from a control group. The different effect of smoking on the disease course between our 
study and former studies that showed a detrimental effect of smoking,6-12 could be explained 
by the longer follow-up period of our study (mean 13 years vs. 3-10 years). Furthermore, 
there are limitations to some studies that showed a detrimental effect of smoking. Studies 
showed that smoking was a risk factor for recurrence after surgery,10,11,33 but this could not 
be confirmed in other post-operative recurrence studies.13,17,20,34 Cosnes et al. showed in a 
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group of 400 CD patients that smokers needed more steroids and immunosuppressants,8 but 
this was only true for women and there was no effect on the need for surgical intervention. 
In another study from Cosnes et al. the negative role of smoking was also only present in 
female CD patients.26 We observed no detrimental effect of smoking in female CD patients. 
The follow-up of patients at our outpatient clinic is independent of complaints. It is therefore 
unlikely that our results are biased by patients who have withdrawn from follow-up because 
of dissolving symptoms after smoking cessation, and therefore were not included in our study. 
Our results are not biased by the drastic decline in active smokers between diagnosis and 
end of follow-up, because a subgroup analysis only showed a higher need for iv steroids in 
the continuous smokers. Early introduction of immunomodulators or biologicals in smoking 
CD patient could bias the results for hospitalizations and surgery.8 However, only 57% of our 
patients were on immunomodulators and/or biologicals without any differences between 
smokers and never smokers. 
Surprisingly, in contrast to active smoking, we found a detrimental effect of passive smok-
ing in never smokers on the disease course of CD. Never smoking CD patients regularly ex-
posed to cigarette smoke more often needed immunosuppressants and infliximab than rarely 
exposed patients, while their follow-up was much shorter. Since levels of nicotine metabolites 
are much lower in passive than in active smokers,35,36 we think that other factors in an envi-
ronment with tobacco smoke pollution than nicotine are involved. To confirm our findings, 
studies with levels of nicotine metabolites for defining passive smokers are needed.
We showed no effect of active smoking on the efficacy of the anti-TNF-α antibody inflixi-
mab in CD patients. Literature about infliximab and smoking is ambiguous. Some studies 
showed no effect of smoking on the response to infliximab,37,38 but a smaller study showed 
that in 59 patients with luminal disease non-smokers responded better to infliximab than 
smokers (73% versus 22%; P<0,001).39 Recently, there was also no effect of smoking on 
outcome in CD in a study comparing a top-down and a step-up strategy with infliximab.40 
Studies with the anti-TNF-α antibody certoluzimab also did not show an effect of smoking on 
efficacy (data on file union chimique belge).41 
Our study did confirm the positive effect of smoking on UC. Even with a longer follow-up, 
smokers needed less often colectomy (12%) than never smokers (28%) with an OR of 0.27 
(95% CI 0.11-0.67). This is in agreement with a meta-analysis (1,489 patients) showing 
an OR of 0.57 (95% CI 0.38-0.85) for a colectomy in current smokers compared to non-
smoking UC patients.23 Never smokers also had more backwash-ileitis than smokers. In 
addition, a clear dose-dependent effect of smoking was observed in UC. Heavy smoking 
UC patients needed fewer steroids, immunosuppressants and hospitalizations, and in heavy 
smokers the disease was more often limited to the rectum. Recently, it was shown that pack-
years were associated with less extensive disease.42 No beneficial effect of passive smoking 
could be established. In fact, passive smoking UC patients had more ileal disease (pouchitis 
and backwash-ileitis) than non-passive smoking UC patients. Further studies concerning the 
effect of passive smoking on UC are needed. 
The differences between quitters before and after diagnosis of UC indicate that smoking 
cessation after diagnosis is detrimental for UC patients. Quitters after diagnosis needed 
more oral steroids and hospitalizations than quitters before diagnosis. Smoking is consid-
ered a protective environmental factor. Patients who quit smoking after diagnosis developed 
ulcerative colitis despite their smoking. Probably there are genetic or other environmental 
factors that make them more prone for developing ulcerative colitis. So when after the diag-
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nosis another factor favouring activity of the colitis occurs, like smoking cessation, the dis-
ease course worsens. This may implicate that patients who experience worsening of disease 
after smoking cessation could benefit more from smoking than patients who quitted smoking 
before diagnosis.
PSC is an infamous extraintestinal disorder in IBD, particularly associated with UC. We 
showed in multivariate analysis an important association between PSC and non-smoking 
in UC (OR 4.32; 95% CI, 1.52-12.25). This is in accordance with other studies43-45 and is 
also reported for PSC without underlying IBD.45 Just like in UC, the protective mechanism of 
smoking on the development of PSC has not yet been clarified. Probably there is a similar 
mechanism.
It is important to note the putative limitations of our study. The retrospective design may 
have led to bias in the interpretations of the data. Asking about smoking behaviour in the 
past and the influence of the diagnosis of the disease on smoking behaviour, could intro-
duce a recall bias. This was counteracted by comparing answers from the questionnaire 
with data from the medical charts, but information about passive smoking was not available 
from the charts. Using a survey may lead to selection bias, but the high response-rate to our 
questionnaire (82%) makes it highly likely that this study is well representative of the smok-
ing behaviour in our IBD population. So it is unlikely that our results are biased by using a 
questionnaire, especially for active smoking. 
In conclusion, no effect of active smoking was shown on the course of CD, but passive 
smoking was detrimental for CD patients. In UC, active smoking had dose-dependent ben-
eficial effects on the course of the disease, while passive smoking seems detrimental for the 
ileum of these patients. The differences in active smoking behaviour at diagnosis between 
CD patients, the general population and UC patients were confirmed, but the number of 
present smokers in CD is lower than in the general population. Passive smoking is a novel 
risk factor for IBD. 
Effects of  active and passive smoking on IBD
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Smoking is detrimental for Crohn’s disease (CD), but beneficial for ulcerative colitis (UC). 
Previously we studied the effects of active and passive smoking in CD and UC patients from 
a university hospital. The present study was conducted to assess the same effects in patients 
from a regional hospital.
Methods: 
A questionnaire focussing on cigarette smoke exposure was sent to 382 patients. Returned 
questionnaires (84%: 128 CD and 192 UC patients) were incorporated into a retrospective 
chart review about disease behaviour and received therapy.
Results: 
At diagnosis there were 52% (95% confidence interval (CI): 43%-60%) smokers among CD 
patients, 40% in a control population and 25% (95% CI: 18%-31%) among UC patients. 
There were less former (19% vs. 31%; p=0.013) and never smokers at diagnosis (30% vs. 
44%; p=0.009) in CD than in UC. No detrimental effects of active or passive smoking 
on the course of CD were observed. UC patients who continued smoking after diagnosis 
needed less often two or more hospitalizations than never smokers (5% vs. 25%; p=0.036). 
Otherwise no clear beneficial effects of active smoking on UC were observed.  Passively 
smoking UC patients experienced more often extraintestinal manifestations (25% vs. 7%; 
p=0,029) than non-passive smokers.
Conclusion: 
Also in a regional hospital inflammatory bowel disease population smoking is a risk factor to 
develop CD and protects against developing UC. We found no detrimental effects of smok-
ing on the course of CD and no clear beneficial effects on the course of UC.
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Introduction
Smoking is a well established environmental factor in inflammatory bowel disease (IBD) with 
remarkable opposite effects on Crohn’s disease (CD) and ulcerative colitis (UC). Smoking is 
a risk factor for developing CD, but it protects against developing UC.1,2 In addition, smoking 
is also unfavourable for the disease course of CD with a higher need for steroids, azathio-
prine and surgery in smokers than in non smokers.3-9 In contrast, smoking is beneficial for 
the disease course of UC with a lower need for hospitalizations, steroids and colectomy in 
smokers than in non smokers.9-15 Recently, we studied the effects of smoking in a Dutch IBD 
population from a university hospital.16 We confirmed the effects of active smoking on the 
development of CD and UC, with 52% smokers in CD, 41% in the control population and 
28% in UC. We also confirmed the beneficial effect of active smoking in UC and moreover 
showed that this beneficial effect was dependent on the daily cigarette dose. However, we 
could not confirm the unfavourable effects of active smoking on the disease course of CD.
In addition to the effects of active smoking, we also studied the effects of passive smoking 
on the disease course in our previous study. These were not in line with the effects of active 
smoking. First, our data suggested a detrimental effect of passive smoking on the disease 
course of CD while active smoking had no effect. Never smoking CD patients regularly 
exposed to cigarette smoke more often needed immunosuppressants and infliximab than 
rarely exposed patients. Second, in UC no beneficial effect of passive smoking on the dis-
ease course was found while active smoking was beneficial. In fact, passive smoking UC 
patients had more ileal disease (pouchitis and backwash-ileitis) than non-passive smoking 
UC patients.
So the results of our previous study on the effects of active and passive smoking on IBD 
were somewhat unexpected, mainly because the detrimental effect of active smoking on CD 
was not confirmed, but also because of the finding of opposite effects of active and passive 
smoking. This could be caused by having performed our study in a university hospital with 
an important referral function for the northern part of the Netherlands. Studying patients 
referred from other hospitals causes a selection bias, since CD patients with a more benign 
disease course are underrepresented.17 The aim of the present study was to see whether our 
previous findings could be confirmed in an IBD cohort from a regional hospital. For this 
purpose, we analyzed the relationship between active and passive smoking, and the course 




Three-hundred and eighty-two patients who visited the outpatient department of the Medical 
Center Leeuwarden in Leeuwarden, the Netherlands, in 2006 and 2007, and who had a 
confirmed diagnosis of CD or UC by endoscopic, radiologic and/or pathologic examina-
tions18 were asked to participate in this study. Patients are seen at a regular basis and more 
often, if needed, at the outpatient department. The Medical Center Leeuwarden is a regional 
hospital and the largest in the province of Friesland. Clinical characteristics and the outcome 
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variables were obtained through retrospective analysis of the medical charts. In addition to 
the information obtained from the charts, detailed information about smoking behaviour 
was obtained through a written questionnaire, which was sent to all 382 patients. Three-
hundred and twenty patients responded to the questionnaire (84%), with 128 CD and 192 
UC patients, and these 320 constituted the final study population. Smoking behaviour at 
diagnosis (median year of diagnosis 1996) of CD and UC patients were compared with 
1996-records of a general, age adjusted Dutch population of the StatLine databank of the 
Dutch central agency for statistics (Statistics Netherlands; http://statline.cbs.nl). The methods 
used were discussed with the medical ethics committee. According to Dutch legislation there 
were no objections against the methods used. A returned questionnaire was considered as 
an informed consent.
Definitions of  smoking behaviour
For defining smoking behaviour, all patients received a detailed questionnaire about smok-
ing behaviour. This included questions about 1) whether the patient had ever been smoking 
and, if so, number of years smoked, and, if a former smoker, number of months after ces-
sation; 2) product smoked and average amount smoked per day; 3) the relation between 
diagnosis and smoking behaviour; 4) passive smoking at present (every day, a few times a 
week, once a week, or never/seldom more than 1 hour a day in the same room with smoking 
persons); 5) educational level; and 6) family history of IBD.
At the time of diagnosis patients were categorized as smokers, former smokers and never 
smokers. A smoker at diagnosis started smoking seven or more cigarettes per week at least 
six months before diagnosis, a former smoker quitted smoking at least six months before 
diagnosis and a never smoker had never smoked until six months before diagnosis.
For studying the relation between smoking and disease course, patients were divided into 
three groups: 1) smokers after diagnosis (smoker at diagnosis who did not stop smoking 
within one year after diagnosis, or former smoker at diagnosis who restarted smoking within 
one year after diagnosis, or never smoker at diagnosis who started smoking within one year 
after diagnosis), 2) former smokers (former smoker at diagnosis who did not restart smoking 
within one year after diagnosis, or smoker at diagnosis who stopped smoking within one 
year after diagnosis) and 3) never smokers after diagnosis (never smoked one year after 
diagnosis).
The level of smoke exposure was analyzed by dividing smokers after diagnosis into two 
groups according to the median number of cigarettes smoked per day. Smoking of one 
cigar was considered equal to four cigarettes, as the average cigar contains four grams 
of tobacco and a cigarette one gram.19 For studying the relation between passive smoking 
and disease course, never smokers after diagnosis were divided into two groups: 1) passive 
smokers (daily, few times a week or once a week exposed to a smoking environment) and 2) 
non-passive smokers (rarely or never exposed).
Clinical characteristics and outcome variables
The patient characteristics and outcome variables we recorded were described before.16 
Shortly, for CD we used the Vienna-classification for describing age at diagnosis (early onset 
<40 years and late onset >40 years), and disease behaviour and location.20 For UC the 
location was defined as proctitis, left-sided colitis and pancolitis with or without backwash-il-
eitis, and determined at diagnosis and as the maximal extend during follow-up. We recorded 
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hospitalizations, surgical procedures, extraintestinal manifestations (EIM), including primary 
sclerosing cholangitis, and the use of 5-aminosalicylates (5-ASA), steroids, azathioprine, 
6-mercaptopurine, methotrexate, cyclosporine and infliximab at any time during follow-up. 
All events were recorded till the end of follow-up (July 2007), or the last date of clinical or 
outpatient visit for patients who were discharged or had withdrawn from outpatient control. 
For UC patients after a colectomy and without development of pouchitis, the date of colec-
tomy was the end of follow-up.
Statistical analysis
The data were analyzed using the Statistical Package for the Social Sciences program ver-
sion 14.0 (SPSS Inc., Chicago, Illinois, USA). Descriptive variables are presented as medians 
(interquartile range (IQR)) and categorical variables as frequencies with percentages. Fre-
quencies were compared with the chi-square test and means between two groups with the 
Mann-Whitney test. Differences are considered significant when p≤0.05. The odds ratios 
(OR) and the 95% confidence intervals (CI) were calculated if appropriate.
Results
Patient characteristics and smoking behaviour
Characteristics of the 320 respondents are presented in table 1. CD patients were more of-
ten female and younger at diagnosis, and more often experienced EIM than UC patients. At 
diagnosis CD patients were more often smokers while UC patients were more often former 
and never smokers. There were 52% (95% CI: 43%-60%) smokers in CD and 25% (95% CI: 
18%-31%) in UC. At the median time point of diagnosis (1996) 40% of the control popula-
tion were smokers. This means an OR of 1.29 (95% CI: 1.07-1.51) for CD and an OR of 
0.61 (95% CI: 0.46-0.77) for UC for being a smoker at diagnosis.
Patient characteristics according to smoking behaviour at diagnosis
In CD, former smokers at diagnosis were older at that time than smokers (38.0 (IQR 27.7-
52.3) vs. 29.7 (22.9-41.7) years; p=0.023) and never smokers (38.0 vs. 26.2 (IQR 19.3-
41.2) years; p=0.008). In UC, there were more females among never smokers at diag-
nosis than among smokers (57% vs. 28%; p=0.001) and former smokers (57% vs. 38%; 
p=0.031). Former smokers at diagnosis had less often an early onset of disease than smok-
ers (43% vs. 66%; p=0.020) and never smokers (43% vs. 71%; p=0.001). Never smok-
ers were the youngest at diagnosis, followed by smokers, whereas former smokers were 
the oldest at diagnosis (30.0 (IQR 22.6-43.6) vs. 34.7 (31.4-47.6) vs. 41.3 (33.8-54.6) 
years; p<0.04). Smokers had more often completed only lower education (35% vs. 19%; 
p=0.046) and less often medium education (30% vs. 51%; p=0.023) than never smokers.
Smokers presented more often with a pancolitis at diagnosis than never smokers (51% vs. 
30%; p=0.021). Since in UC smokers and never smokers differed in gender, we looked at 
differences in pancolitis at diagnosis between females and males. Females presented less often 
with pancolitis at diagnosis than males (28% vs. 45%; p=0.017). Multivariate analysis with lo-
gistic regression revealed that gender was an independent risk factor for pancolitis at diagnosis 
(OR for females: 0.52; 95% CI: 0.27-1.00), but smoking behaviour at diagnosis was not.
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Table 1. Characteristics of  the Crohn’s disease and ulcerative colitis patients responding to the question-
naire
Characteristic: n (%) CD (n=128) UC (n=192) p-value
Gender: female 79 (61.7) 84 (43.8) 0.002
Age at diagnosis:
  median (yrs) (IQR) 







Follow-up: median (yrs) (IQR) 10.4 (3.8-20.5) 8.3 (3.5-17.1) ns
Education:    












Family history of  IBD 29/116 (25.0) 41/170 (24.1) ns
Smoking behaviour at diagnosis:
  smoker
  former smoker










EIM 31 (24.2) 17 (8.9) <0.001
Primary sclerosing cholangitis 1 (0.8) 6 (3.1) ns
Location CD:
  terminal ileum
  colon
  ileocolon






























*: B1: non-stricturing, non-penetrating; B2: stricturing; B3: penetrating.
CD: Crohn’s disease; EIM: extraintestinal manifestations; IQR: interquartile range; UC: ulcerative colitis.
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Disease outcome in CD
Active smoking
The relation between smoking behaviour after diagnosis and disease outcome in CD is 
shown in table 2. There were no differences between smokers and never smokers after diag-
nosis for the outcome variables, except that smokers after diagnosis had less often stricturing 
disease behaviour than never smokers. Smokers needed less often one or more hospitaliza-
tions and received less often iv steroids than former smokers.
Thus no main differences between the outcome of smokers and never smokers were ob-
served. It is possible that these findings are biased by our definition of smokers after diag-
nosis, that is, no smoking cessation within one year after diagnosis. Following this definition 
a patient that stopped smoking two years after diagnosis is called a smoker after diagnosis. 
Some of our so-called smokers after diagnosis probably have stopped smoking more than a 
year after diagnosis, since there is a drastic decline in active smokers between time of diag-
nosis and end of follow-up (from 52% to 28%). Therefore, we composed a subgroup of pa-
tients that smoked during the complete follow-up and compared them with the never smok-
ers at the end of follow-up. This analysis showed no differences for the outcome variables, 
except that the subgroup of smokers had more often localisation of the disease proximal to 
the terminal ileum than never smokers (14% vs. 0%; p=0.022). We did not observe differ-
ences in outcome between smokers and never smokers among female CD patients either.
We also studied the effects of number of cigarettes smoked per day on the disease course 
in smokers after diagnosis. This analysis showed no differences for the outcome variables, 
except that CD patients smoking ten or less cigarettes per day (n=30) needed more often 
one or more hospitalizations (80% vs. 50%; p=0.018) and had less often non-stricturing, 
non-penetrating disease behaviour (30% vs. 61%; p=0.019) than patients smoking more 
than ten cigarettes per day (n=28).
Passive smoking
For studying the effects of passive smoking on the disease course of CD, never smoking pa-
tients were divided in passive (n=14) and non-passive smokers (n=22). This analysis showed 
no differences for the outcome variables.
Disease outcome in UC
Active smoking
The relation between smoking behaviour after diagnosis and disease outcome in UC is 
shown in table 3. No differences were observed for the outcome variables. Smokers after 
diagnosis more often had pancolitis at diagnosis, and subsequently as maximal localization 
during follow-up, than former and never smokers. Thus, we did not observe a beneficial ef-
fect of active smoking on UC. As suggested above in CD, it is possible that these findings 
are biased by our definition of smokers after diagnosis, since there is also a drastic decline 
in active smokers between time of diagnosis and end of follow-up in UC (from 25% to 13%). 
Therefore, we composed a subgroup of patients that smoked during the complete follow-
up and compared them with the never smokers at the end of follow-up. This subgroup of 
continuing smokers used less often topical 5-ASA (64% vs. 87%; p=0.010) and needed less 
often two or more hospitalizations (5% vs. 25%; p=0.036) than never smokers.
We also studied the effects of number of cigarettes smoked per day on the disease course 
in smokers after diagnosis. No differences were observed on the outcome variables between 
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patients smoking twelve or less cigarettes per day (n=20) and patients smoking more than 
twelve cigarettes per day (n=19).
Passive smoking
Never smoking UC patients were divided in passive and non-passive smokers. Passive smok-
ers (n=24) experienced more often EIM (25% vs. 7%; p=0,029) than non-passive smokers 
(n=55). No differences were observed for the other outcome variables.
Table 2. Outcome variables for Crohn’s disease according to smoking behaviour after diagnosis






Follow-up: median (yrs) (IQR) 11.4 (4.8-21.2) 9.6 (3.3-24.4) 9.9 (2.4-19.7)
Hospitalizations:
  at least one








  at least one




































IS¶ 28 (47.5) 19 (59.4) 16 (43.2)
Infliximab 3 (5.1) 2 (6.3) 3 (8.1)
EIM 13 (22.0) 6 (18.8) 12 (32.4)




  ileocolon 


























*: p ≤ 0.05 vs smokers. ¶: Azathioprine, 6-mercaptopurine and/or methotrexate. §: B1: non-stricturing, non-
penetrating; B2: stricturing; B3: penetrating.
5-ASA: 5-aminosalicylates; EIM: extraintestinal manifestations; IQR: interquartile range; IS: immunosup-
pressants.
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Table 3. Outcome variables for ulcerative colitis according to smoking behaviour after diagnosis




Follow-up: median (yrs) (IQR) 9.2 (4.0-19.2) 8.2 (3.6-12.4) 8.2 (3.2-17.6)
Hospitalizations:
  at least one







Colectomy 3 (7.7) 13 (18.8) 8 (9.5)
Pouch 0 5 (7.2) 5 (6.0)
Pouchitis 0 4/5 (80.0) 3/5 (60.0)





























IS¶ 8 (20.5) 19 (27.5) 28 (33.3)
Cyclosporine 2 (5.1) 1 (1.4) 2 (2.4)
EIM 2 (5.1) 5 (7.2) 10 (11.9)
Primary sclerosing cholangitis 1 (2.6) 1 (1.4) 4 (4.8)
Location at diagnosis:
  proctitis
  left-sided 
















  left-sided 















  to pancolitis/ backwash 8/15 (53.3) 12/43 (27.9) 22/52 (42.3)
*: p ≤ 0.05 vs. smokers. ¶: Azathioprine, 6-mercaptopurine and/or methotrexate.
5-ASA: 5-aminosalicylates; EIM: extraintestinal manifestations; IQR: interquartile range; IS: immunosup-
pressants.
Comparison of  patients from the regional hospital with patients from a tertiary 
referral hospital
Finally, we compared the disease course between patients from the present study and pa-
tients from our previous study.16 In CD, we confirmed that patients from a regional hospital 
have a more benign disease course; they needed less often one or more surgical procedures 
(47% vs. 58%; p=0.023) and infliximab (6% vs. 19%; p=0.001), and had more often 
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localisation of the disease only in the colon (35% vs. 26%; p=0.042) and non-stricturing, 
non-penetrating disease behaviour (45% vs. 34%; p=0.027) than patients from the univer-
sity hospital (n=380). On the other hand, patients from the regional hospital had more often 
iv administration of steroids (21% vs. 10%; p=0.002).
In UC, we also found a more benign disease course in patients from the regional hospital; 
they needed less often a colectomy (13% vs. 20%; p=0.025) and topical steroids (28% vs. 
68%; p<0.001) than patients from the university hospital (n=295). An exception on this was 
that patients from the regional hospital more often had pancolitis as maximal localization 
during follow-up (62% vs. 46%; p<0.001).
Discussion
Smoking is a remarkable risk factor for CD and UC, the two most common IBDs. Smoking 
is detrimental for the development and course of CD, while smoking is beneficial for the 
development and course of UC. In our previous study in an IBD population from a Dutch 
university hospital we confirmed these effects of smoking on the development of both CD 
and UC, and on the disease course of UC.16 However, we did not observe a detrimental ef-
fect of active smoking on the course of CD. The present study was conducted to see whether 
our findings could be confirmed in an IBD population from a regional hospital. We indeed 
confirmed that in a regional hospital population smoking is a risk factor for developing CD 
and protects against developing UC, with more active smokers at diagnosis in CD, and 
more former and never smokers in UC. And as in the university hospital population, we did 
not observe a detrimental effect of active smoking on the disease outcome in CD. However, 
we did not confirm that active smoking was beneficial for the course of UC, although in a 
subgroup analysis continuing smokers needed less often two or more hospitalizations than 
never smokers.
So we confirmed in this IBD population from a regional hospital that smoking is a risk fac-
tor for developing CD and protective for UC. At diagnosis there were 52% smokers in CD, 
40% in the control population and 25% in UC. These numbers are comparable with those 
from our university population with 52% smokers in CD and 28% in UC.16 In a recent meta-
analysis of 1,679 CD and 2,459 UC patients active smokers had an OR of 1.76 (95% CI: 
1.40-2.22) for developing CD and an OR of 0.58 (95% CI: 0.45-0.75) for developing UC.2 
Former smokers had an increased risk for UC (OR 1.79; 95% CI: 1.37-2.34). More than 
half of the patients in this meta-analysis were from regional hospital IBD populations.
In contrast to most reports so far, we neither observed a detrimental effect of smoking on the 
disease course of CD in a regional nor in a university hospital population from the Nether-
lands. In fact, in the present study smokers needed less often a hospitalization and iv steroids 
than former smokers, and heavy smoking CD patients needed less often a hospitalization 
and had more often non-stricturing, non-penetrating disease behaviour than light smokers. 
Other studies could also not confirm the detrimental effect of smoking on CD.11-13,15,21-24 Of 
these studies, two were performed in regional hospital populations.11,15 Of the studies show-
ing a detrimental effect only a few were performed in regional hospital populations.3,7 The 
question remains why we do not observe a detrimental effect of smoking in our CD patients 
from a regional and a university hospital. The length of follow-up in our regional hospital 
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population (mean 13.5 years) is comparable with that of our university hospital population 
(mean 13 years) and is longer compared to that in studies that showed a detrimental effect 
of smoking (between 3 and 10 years).3-8 A possible bias, especially for the results on hos-
pitalizations and surgery, could be early introduction of immunosuppressants or biologicals 
in smoking CD patients.5 However, only 50% of our patients were on immunosuppressants 
and/or biologicals without any differences between smokers and never smokers.
We did not observe a clear positive effect of smoking on the course of UC patients from 
this regional hospital population, although from a subgroup of continuing smokers after 
diagnosis fewer needed two or more hospitalizations than never smokers. In our study in 
the university hospital population we found a lower colectomy rate in smokers than in never 
smokers (12% vs. 28%),16 and a meta-analysis (1,489 patients) showed an OR of 0.57 (95% 
CI: 0.38-0.85) for a colectomy in current smokers compared to non-smoking UC patients.9 
The fact that we did not observe a beneficial effect of smoking on colectomy rate in the re-
gional hospital population could be caused by a lack of power considering the low number 
of smokers (39) and a lower colectomy rate in the regional than in the university hospital 
population (13% vs. 20%).
In the present study we could not confirm our findings in our university hospital population 
on the role of passive smoking in both CD and UC.16 In that population our data suggested 
a detrimental effect of passive smoking on both CD (passive smokers needed more often im-
munosuppressants and infliximab) and UC (passive smokers had more ileal disease (pouchi-
tis and backwash-ileitis)). Both findings were not in line with the effects of active smoking in 
that study (no effect of active smoking in CD and beneficial effect of active smoking in UC). In 
the present study, we found no effect of passive smoking in CD. In UC, passive smokers more 
often experienced EIM, but we found no differences for ileal disease. However, the latter was 
not surprising, since pouchitis and backwash-ileitis were seldom seen in our regional hospital 
population. Considering our inconsistent findings regarding the effects of passive smoking 
in itself and compared to active smoking, studies about the effects of passive smoking have 
to be repeated, ideally with measurements of biochemical markers of passive smoking such 
as urinary cotinine levels.
The present study has a number of limitations. The retrospective design may have led to 
bias in the interpretation of the data. A retrospective design could also lead to bias by includ-
ing only patients who require follow-up. However, it is unlikely that our results are biased 
by patients who have withdrawn from follow-up because of resolving symptoms, since the 
follow-up of patients at the outpatient clinic is at a regular basis and more often, if needed. 
Using a questionnaire on smoking behaviour in the past could introduce a recall bias. Using 
a survey may lead to selection bias, but the high response rate to our questionnaire (84%) 
makes it highly likely that this study is well representative of the smoking behaviour in this IBD 
population. Another limitation is that patients were divided into three groups (smokers after 
diagnosis, former and never smokers) instead of the four groups (smokers after diagnosis, 
quitters before and after diagnosis and never smokers) in our previous study in the university 
hospital population. We chose for this division in three groups because otherwise groups be-
came too small. However, the definitions of the smokers after diagnosis and the never smok-
ers after diagnosis are the same in both studies, making comparisons between both studies 
still possible. Finally, the numbers of patients studied in the present study are lower than in 
our previous study, which could contribute to unexpected and/or non significant results.
In conclusion, we confirmed that in both a regional and university hospital population 
Smoking in regional IBD population
66
smoking is a risk factor for CD and protective against the development of UC. In contrast 
to most reports, we neither observed a detrimental effect of active smoking on the disease 
course of CD in a regional nor a university hospital population. For UC, we found no clear 
beneficial effect of smoking on the disease course in this regional hospital population. For 
passive smoking, we could not confirm that passive smoking is detrimental for CD and/or for 
ileal disease in UC, as suggested in our university hospital population. The role of passive 
smoking in IBD needs further exploration.
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Smoking behaviour and genetic variations are important factors for the development of 
Crohn’s disease (CD), but studies investigating the interaction between smoking and genetic 
background are scarce. We studied allelic associations of 19 confirmed variants located in 
14 CD-associated genes or loci, in CD patients stratified for active smoking at diagnosis and 
passive smoking in childhood.
Methods: 
Genotyping data of 19 CD-associated single nucleotide polymorphisms (SNPs) were avail-
able for 310 CD patients and 976 controls. Data on active smoking at diagnosis and passive 
smoking in childhood were obtained through a written questionnaire and review of medical 
charts.
Results: 
Loci associated in smoking, but not in non-smoking, CD patients were 5p13.1 (rs17234657), 
DLG5 (rs2165047), NKX2-3 (rs10883365) and NOD2 (R702W). Loci associated in non-
smoking, but not in smoking, CD patients were IL23R (rs7517847), 5p13.1 (rs9292777), 
IRGM (rs13361189 and rs4958847), IL12B (rs6887695) and CCNY (rs3936503). PTPN2 
(rs2542151) was only associated in the smoking CD cohort (P=0.041), and not in the en-
tire cohort (P=0.23) and the non-smoking CD cohort (P=0.80). In passively smoking CD 
patients associations with 13 SNPs in 9 loci were found, including PTPN2. In non-passively 
smoking CD patients only associations with NOD2 (1007fsinsC and G908R) were found. 
Conclusion: 
The difference in associated genes between smoking and non-smoking CD patients implies 
a complex gene-environment interaction. Therefore, genetic studies in CD should be strati-




Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic re-
lapsing inflammation of the gastrointestinal tract. Development of CD is influenced by both 
environmental factors and the genetic background. One of the most important environmen-
tal risk factors is smoking. Several studies have shown that CD patients are more likely to be 
smokers than their matched controls.1-4 In addition, CD patients are more often exposed to 
tobacco smoke in childhood than controls.5,6 So active smoking, and possibly also passive 
smoking, seems to be an important risk factor for the development of CD. 
Development of CD is also influenced by the genetic background and the role of genetic 
variants has been the subject of intensive research the last decade. The first identified CD 
associated gene was CARD15 on chromosome 16 encoding for the protein NOD2.7,8 After 
the introduction of genome-wide association studies, there has been a enormous progress in 
the unravelling of the genetic background of CD, with more than 30 confirmed susceptibility 
loci to date.9 
Although it is likely that development of CD is partly caused by an interaction between en-
vironmental factors such as smoking, and the genetic background, studies on the interaction 
between smoking and genetic variants are scarce. In a Spanish CD population of 178 pa-
tients the prevalence of the three CD-related mutations in the NOD2 gene (R702W, G908R 
and 1007fsinsC) in smokers and non-smokers were studied and only the 1007fsinsC muta-
tion was more frequent in non-smokers.10 Two other studies of 338 and 232 CD patients 
showed that NOD2 variants and smoking behaviour were independent risk factors for CD, 
but there was no specific interaction between them.11,12 In a Hungarian CD population of 
527 patients no difference was found in the proportion of smokers between carriers and non-
carriers of NOD2 variant alleles.13 Finally, smoking status was combined with TUCAN, IBD5, 
NOD1-2 and TNFSF15 genotypes in a diagnostic panel to generate a risk scoring system for 
CD, but the interaction between smoking and the genetic variants was not studied.14
The aim of our study was to explore differences in genetic variants in relation to smoking 
status. For this purpose we used data available from previous studies 4,15-17 and selected three 
NOD2 variants and 16 confirmed CD associated single nucleotide polymorphisms (SNPs), 
and studied the allelic associations in CD patients stratified for smoking status at diagnosis 
and for passive smoking in childhood.
Methods 
Subjects
DNA samples were available for 310 CD patients from the University Medical Center Gro-
ningen, the Netherlands. Diagnosis of CD was based on accepted clinical, radiologic, en-
doscopic and histopathological criteria.18 The controls consisted of 976 healthy volunteers 
recruited from the University Medical Center Utrecht, the Netherlands, and have been previ-
ously described.15 All participants were of European Caucasian descent and gave informed 
consent. The study was approved by the ethics review committees of the participating hospi-
tals. All DNA samples and data in this study were handled anonymously.
Patient characteristics recorded were gender, age at diagnosis (divided in early age onset 
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(<40 years) and late onset disease (>40 years) according to Vienna-classification),19 time of 
diagnosis (defined as the date of the first detection of inflammatory abnormalities by radio-
logical, endoscopic or peroperative examinations), disease behaviour and location accord-
ing to Montreal-classification,20 and extraintestinal manifestations.
Genotyping and SNP selection
Genotype data was available from previous studies and genotyping methods have been 
described before.15-17 For the current study we included 19 SNPs located in 14 confirmed CD 
susceptibility loci (table 2).
Data on smoking behaviour
Information on active smoking behaviour at diagnosis was obtained from medical charts and 
from a written questionnaire that we described before.4 Patients were divided in smokers and 
non-smokers at diagnosis. Smokers were defined as having started smoking seven or more 
cigarettes per week at least six months before diagnosis. Non-smokers were defined as never 
smokers at diagnosis and smokers who quitted smoking six or more months before diagno-
sis. In five of 310 CD patients it was not possible to define smoking behaviour at diagnosis. 
Smoking behaviour at diagnosis (median year of diagnosis was 1995) of CD patients was 
compared with 1995-records of a general, age adjusted Dutch population of the StatLine 
databank of the Dutch central agency for statistics (Statistics Netherlands; http://statline.cbs.
nl), as described before.4
Information on passive smoking in childhood was obtained from the same written ques-
tionnaire, which also included questions about passive exposure to cigarette smoke in child-
hood. Patients were asked whether they were exposed to cigarette smoke at home being a 
child. With this information patients were divided in passive smokers (exposed to cigarette 
smoke) and non-passive smokers (not exposed to cigarette smoke). For 225 of the 310 CD 
patients information about passive smoking in childhood was available.
 
Statistical analysis
For patient characteristics, continuous variables are presented using medians (range) and 
categorical ones using frequencies with percentages. Data were analyzed using the Statistical 
Package for the Social Sciences program version 12.0 (SPSS Inc., Chicago, Illinois, USA). 
Continuous variables were compared with the Mann-Whitney test and categorical ones with 
the chi-square test. Differences in allele distribution between cases and controls, and within 
cases were tested for significance by the chi-square test. Odds ratios (OR) and 95% confi-
dence intervals (CI) were calculated using Woolf’s method with Haldane’s correction. The 
significance threshold for P values was set at <0.05.
Results
Patient characteristics
The characteristics of all 310 CD patients are listed in table 1. Most patients were female, 
had an early onset of disease and a history of surgical intervention. The percentage of pa-
tients that were smokers at diagnosis (54% (95%CI: 48.1%-59.4%) is higher than the 41% 
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smokers in the general population at the median time point of diagnosis (1995).4
Clinical characteristics of smokers were compared to those of non-smokers. Smokers were 
older at diagnosis than non-smokers (median 29.2 vs 25.1 years; P=0.021) and smokers 
were more often exposed to cigarette smoke in childhood than non-smokers (77.2% vs 
63.4%; P=0.023). No differences for the other clinical characteristics listed in table 1 were 
observed. In addition, at diagnosis we looked at a combined effect of NOD2 status and 
smoking behaviour on disease location and behaviour. No differences were found for pa-
tients with any NOD2 variant divided in smokers and non-smokers, and for smoking patients 
divided in patients with no NOD2 variants and with any NOD2 variant on this matter.
Allelic association analysis stratified for smoking behaviour at diagnosis
The results of the allelic association analysis between the entire cohort of 310 CD patients 
and 976 healthy controls are shown in table 2 and supplementary table 1. Fourteen SNPs 
located in 10 loci were statistically significant associated with CD in this cohort. We then 
analyzed whether the genetic associations were different between the cohorts of smoking and 
non-smoking CD patients. The results of the allelic association analysis stratified for smoking 
behaviour at diagnosis are also depicted in table 2. In both smoking and non-smoking CD 
patients allelic associations with IL23R (rs11209026) and NOD2 (1007fsinsC and G908R) 
were found. In smoking, but not in non-smoking CD patients, associations with 5p13.1 
(rs17234657), DLG5 (rs2165047), NKX2-3 (rs10883365) and NOD2 (R702W) were found. 
Table 1. Characteristics of  310 CD patients
Characteristic: n (%)
Gender: female 203 (65.5)
Age at diagnosis (years):
  median (range)
  early onset (<40 years)
26.6 (7.5-73.9)
234 (75.5)
Follow-up (years) median (range) 11.0 (1.4-51.4)
Smoking at diagnosis 164/305 (53.8)








Upper GI tract 19 (6.1)
Disease behaviour:






Peri-anal disease 88 (28.4)
Extraintestinal manifestations 55 (17.7)
Family history of  IBD 90 (29.0)
History of  surgical intervention 206 (66.5)
CD - Crohn’s disease; GI - gastrointestinal; IBD - inflammatory bowel disease.
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In non-smoking, but not in smoking, CD patients associations with IL23R (rs7517847), 
5p13.1 (rs9292777), IRGM (rs13361189 and rs4958847), IL12B (rs6887695) and CCNY 
(rs3936503) were found. PTPN2 (rs2542151) was not associated in the entire cohort, 
but showed association in the smoking CD group and not in the non-smoking CD group. 
A direct within cases analysis showed no significantly differential distribution between smok-
ing and non-smoking CD patients (table 3).
Allelic association analysis stratified for passive smoking in childhood 
Next we divided CD patients according to exposure to cigarette smoke during childhood and 
analyzed whether genetic associations were different between cohorts of passive smoking 
and non-passive smoking CD patients. The results of the allelic association analysis stratified 
for passive smoking in childhood are shown in table 4 and supplementary table 2. In passive-
ly smoking CD patients associations with 12 SNPs located in eight CD susceptibility loci were 
found, including the PTPN2 (rs2542151) locus again. However, in non-passively smoking 
CD patients only associations with NOD2 (1007fsinsC and G908R) were found. The strong 
association in passive smokers with both SNPs in IRGM (rs13361189 and rs4958847) is 
remarkable since they were considerably less significantly associated in the entire CD cohort 
and not associated in the actively smoking CD cohort (see also table 2). A direct within cases 
analysis showed no significantly differential distribution between passively smoking and non-
passively smoking CD patients.
Allelic association analysis stratified for passive smoking in childhood in CD 
patients with an early onset of  disease
If passive smoking in childhood has a relationship with the development of CD, than this 
is most likely the case for patients with an early onset of CD. Therefore, we analyzed CD 
patients with an early onset of disease (40 years or younger) for genetic associations be-
tween the cohorts of passive smokers and non-passive smokers in childhood (table 5 and 
supplementary table 3). In passive smokers with an early onset the same associations were 
shown as for all passive smokers, except for the IL23R (rs7517847) and IL12B (rs6887695) 
loci. In non-passive smoking CD patients with an early onset associations with four SNPs lo-
cated in three CD susceptibility loci were found, including the IL23R (rs7517847) and 1q24 
(rs12035082) loci. A direct within cases analysis between passive smoking and non-passive 
smoking CD patients with an early onset showed an association with the IBD5 (rs2522057) 
locus (P=0.037; OR: 1.71 (95%CI: 1.03-2.85)). Furthermore, we analyzed whether passive 
smoking in childhood was related with a younger age at diagnosis in CD patients with the 
same genetic predisposition. For this purpose, we compared for each of the 14 CD loci the 
age at diagnosis between passive and non-passive smokers in childhood carrying at least 
one risk allele of the locus involved. This analysis showed no differences in age at diagnosis 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The aim of the current study was to explore whether there are differences in the genetic back-
ground of CD patients in relation to smoking behaviour. First, we found that many previously 
described genetic associations in large cohorts remain statistically significant in a relatively 
small subset of 310 CD patients of these described cohorts.16,17 We then stratified these pa-
tients according to their smoking behaviour at diagnosis and secondly to their exposure to 
cigarette smoke during childhood. All these data were available from previous studies.4,15-17 
We found a striking difference of associated alleles in smoking CD patients compared to non 
smoking patients, implying a complex pattern of gene-environment interaction. However, 
no associations were found in the within cases analysis between smokers and non-smokers, 
which is probably caused by the small subgroups.
The question is how to interpret these results. This study has two disadvantages. First, the 
lack of smoking data of the control population limits the possibility of interaction analysis 
using a logistic regression model (multiplicative or statistical interaction). Therefore we could 
not evaluate the gene-environment interaction properly. This is an important issue in general, 
since most case-control studies that are performed in complex diseases lack data on environ-
mental factors, particularly with respect to the control groups that are being used. Second, 
the small numbers of patients in the subgroups leading to a lack of power is another issue 
of concern, particularly with respect to passive smoking. In the case-control analyses of the 
patients exposed to cigarette smoke during childhood, the differences could be explained by 
chance findings due to the small number of patients in the non-passive smoking group. In 
the analysis stratified for active smoking at diagnosis lack of power does not seem to explain 
all the differences, since several loci (IRGM, DLG5, NKX2-3) are associated in one of the two 
groups, while the P value and OR in the other group do not show any association or even a 
trend towards association.
An even more intriguing finding is that PTPN2 is not associated in the entire group (P=0.23) 
or in the non-smokers group (P=0.79), but is associated with CD in the smoking at diag-
nosis (P=0.041) and the passive smoking in childhood groups (P=0.025). In addition, in 
the analysis between active smokers and non-smokers the P-value for PTPN2 is 0.09 (table 
3) and the association will become most likely significant in larger cohorts. Association with 
this locus was reported for the first time by the Wellcome Trust Case Control Consortium.21 
PTPN2, protein tyrosine phosphatase nonreceptor type 2, is able to reverse tyrosine phos-
phorylation and is important for the regulation of haematopoiesis and in cytokine signal-
ling.22 PTPN2 is also associated with rheumatoid arthritis (RA) and type 1 diabetes.21 In both 
these autoimmune diseases, smoking is also an important environmental factor. Smoking is 
the best established environmental risk factor for RA23-25 and maternal smoking in pregnancy 
has protective effects on type 1 diabetes.26-28 Another tyrosine phosphatase nonreceptor, 
PTPN22, which is a critical gatekeeper of T cell receptor signalling, is associated with RA.29 
Interestingly, for this particular gene, gene-environment interaction with cigarette smoking 
for more than 10 pack-years is observed in RA.30 These findings further support the idea 
that specific environmental factors are necessary for specific genetic variants to contribute to 
disease development.
Despite the limitations of the current study, it is clear that when our cohort is stratified for 
smoking, many different genetic associations become apparent and genes like PTPN2 are 
only associated in a subgroup. This is an important finding since most genetic case-control 
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studies are not stratified for environmental factors and are not matched with data on envi-
ronmental factors in the control cohorts. In studies with only limited sample size true genetic 
associations might therefore be missed. In IBD, a large part of the disease pathogenesis 
consists of (yet unknown) environmental factors and their interaction with the genetic back-
ground of the patient. Extrapolating our findings, even in large cohorts true moderately sized 
associations can be missed, when environmental factors are not taken into account.
Passive smoking in childhood has also been related to the development of CD.5,6 There-
fore we studied differences in genetic associations in CD patients divided in passive and 
non-passive smokers in childhood. In passively smoking CD patients associations with eight 
loci (IL23R, 5p13.1, IRGM, IL12B, DLG5, CCNY, NOD2 and PTPN2) were found, while 
in non-passively smoking CD patients only associations with NOD2 (1007fsinsC, G908R) 
were found. As mentioned before, part of this might be explained by the small subgroup of 
non-passively smoking CD patients (n=65) implying limited statistical power. However, sev-
eral SNPs like IRGM (rs13361189; P=0.99 and rs4958847; P=0.68), DLG5 (rs2165047; 
P=0.60) and NOD2 (R702W; P=0.69) show no association at all and will most likely also 
not be associated in larger non-passively smoking CD cohorts either.
An effect of passive smoking in childhood will probably be the largest in those patients 
with an early onset of CD. Therefore we studied genetic associations between passive and 
non-passive smokers with onset of CD before the age of 40 years. In passive smokers with 
an early onset the same associations were shown as for all passive smokers, except for the 
IL23R (rs7517847) and IL12B (rs6887695) loci. Interesting are the findings in the non-
passively smoking CD patients with an early onset when compared with non-passive smok-
ers in the entire cohort. In non-passive smokers with an early onset associations with IL23R 
(rs7517847), 1q24 (rs12035082) and NOD2 (1007finsC and G908R) were found, while 
in non-passive smokers in the entire cohort only associations with NOD2 were found. This 
might suggest that in non-passive smokers with an early onset genetic background is more 
important than for non-passive smokers with a late onset of CD. However, these results are 
of course for a great part scattered by the decrease in sample size and further research is 
needed in larger cohorts about the true interaction between genetic variants, passive smok-
ing in childhood and early age at diagnosis of CD.
In conclusion, we found different genetic associations in different groups according to 
active smoking at diagnosis and passive smoking in childhood. Part of the difference can 
be explained by the lack of power in this relatively small CD cohort. However, it is clear that 
there is an interaction between genes and the environment. Furthermore, our data suggest 
that in order to find all CD associated genes, particularly those with low odds ratios, we need 
to stratify patient and control cohorts for smoking behaviour, including passive smoking in 
childhood. Therefore, genetic studies in CD, and probably also in ulcerative colitis and RA, 
should be stratified for smoking behaviour, especially in cohorts of limited sample size. Oth-
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Protective effects of  
cigarette smoke on 
ulcerative colitis are 
not related to induced 
heme oxygenase 1 
expression in colonic 
epithelial cells
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Smoking is beneficial for ulcerative colitis (UC), but underlying mechanisms are unknown. 
Induction of heme oxygenase 1 (HO-1) was beneficial in animal models of intestinal injury. 
Cigarette smoke (CS) can induce HO-1, but the effect of smoking on intestinal HO-1 is 
unknown. We studied the effects of smoking on colonic HO-1 expression in vitro, in animals 
and in humans.
Methods: 
DLD-1 cells were incubated with cigarette smoke extract (CSE). Mice were exposed to normal 
air or to CS for eight days. Colon biopsies of healthy human non-smokers and smokers were 
collected. HO-1 expression was evaluated by quantitative polymerase chain reaction (qPCR), 
western blotting and immunohistochemistry. Cytochrome P450 1A1 (CYP1A1) expression 
(qPCR) was used as a positive control for exposure of the colon to CS.
Results: 
CSE dose-dependently induced HO-1 and CYP1A1 mRNA expression in DLD-1 cells. In 
mice and humans, colonic CYP1A1 mRNA expression was increased in subjects exposed 
to CS, but colonic HO-1 mRNA and protein expression were equal between controls and 
subjects exposed to CS.
Conclusion: 
CS does induce a CYP1A1 response, but not a HO-1 stress response in colonic epithelial 
cells. This indicates that CS does not exert its beneficial effect on UC via up-regulation of 
colonic HO-1, but could trigger other protective mechanisms locally in the colon.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by chronic relaps-
ing inflammation of the colon. Smoking is an important environmental factor in UC. Patients 
with UC are less likely to be smokers than controls,1-5 implying that smoking protects against the 
development of UC. Besides this protective effect on the development, smoking also has ben-
eficial effects on the disease course of UC. Smoking was associated with less hospitalizations,5-8 
and decreased need for steroids 5,8,9 and surgery.5-10 Although the beneficial effect of smoking in 
UC is already known for years, it is still unknown which of the more than 4,000 components in 
cigarette smoke (CS) is responsible for this effect and which protective pathways are involved.
One of the pathways involved could be heme oxygenase (HO). HO is the rate-limiting en-
zyme involved in the breakdown of heme, yielding the end-products biliverdin, Fe2+ and carbon 
monoxide (CO). Heme causes oxidative stress, while all three end-products have anti-oxidative, 
anti-apoptotic and anti-inflammatory properties.11-17 Three isoforms of HO are identified: HO-
1, HO-2 and HO-3, of which HO-1 is the only inducible form. It can be induced by heme, but 
also by oxidative stress, ischemia-reperfusion, prostaglandins, hormones, hypoxia and inflam-
matory cytokines.18-21 Induction of HO-1 was beneficial for the intestines in several models of 
oxidative injury and inflammation; it protected the gut against ischemia-reperfusion injury in 
rats,22,23 ameliorated colitis in IL-10 knock-out mice,24 and protected against intestinal damage 
in TNBS-induced colitis in rats 25 and in DSS-induced colitis in mice.26,27 In contrast, inhibition 
of HO-1 expression enhanced intestinal inflammation and injury in TNBS-induced colitis in 
rats 28 and in DSS-induced colitis in mice.29 Taken together, these observations implicate that 
increased expression of HO-1 is a protective defence mechanism against oxidative and inflam-
matory injury of the intestines. Therefore, induction of HO-1 could be beneficial for UC patients 
by protecting against development of UC and/or by ameliorating inflammation in established 
UC.
Considering the beneficial effects of smoking on UC and of HO-1 induction on intestinal 
inflammation, it is interesting that smoking is also able to induce HO. Exposure to CS increased 
HO-1 expression in lung epithelial cells and/or alveolar macrophages in both in vitro 30,31 and 
animal 31,32 studies. In humans, smokers had increased expression of HO-1 in lung tissue 33 
and gingival tissue.34 In addition, CS also induced HO-1 in other cultured human cells like 
monocytes 35,36 and vascular endothelial cells.36 However, the effect of CS on intestinal HO-1 
expression is unknown in vitro, in animals and in humans. 
The aim of this study is to explore whether CS increases the colonic expression of HO-1. For 
this purpose, we studied the effects of smoking in vitro, in mice and in humans.
Methods
Materials
All supplies for cell culture experiments and for quantitative polymerase chain reaction (qPCR) 
analysis were obtained from Invitrogen (Breda, The Netherlands), unless stated otherwise. 
For 100% cigarette smoke extract (CSE), 25 ml serum-free culture medium was saturated 
with smoke from two Kentucky 3R4F research cigarettes (University of Kentucky, Lexington, 
KY, USA) using a peristaltic pump (Watson-Marlow, Rotterdam, The Netherlands).
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Cell culture experiments
To examine whether cigarette smoke affects colonic HO-1 expression in vitro, cells of the 
human colon adenocarcinoma cell line DLD-1 were exposed to CSE. Cells were cultured in 
RPMI-1640 glutamax medium supplemented with 10% v/v heat-inactivated fetal calf serum, 
penicillin (50 U/mL), streptomycin (50 µg/mL) and fungizone (5 µg/mL) in a humidified incuba-
tor at 37°C in an atmosphere containing 5% carbon dioxide. Harvested cells were placed on 
fresh serum-free culture medium and then incubated with 0, 5, 10, 20, 30, 50 or 100% CSE 
for 9 h. Incubating DLD-1 cells with 50 and 100% CSE caused significant cell death and there-
fore we only report the data of incubation with 0-30% CSE. All experiments were performed in 
triplicate. Experiments were started within one hour after preparation of CSE. At the end of the 
experiments, each well was washed with HBSS and harvested in Trizol or lysisbuffer for qPCR 
and western blot analyses, respectively. Samples were stored at -80°C until further use.
Animal experiments
To examine whether cigarette smoke affects colonic HO-1 expression in vivo, female BALB/c 
mice (19-21 g; Harlan, Boxmeer, The Netherlands) were exposed to CS. Mice were housed 
under standard laboratory conditions with free access to standard laboratory chow and wa-
ter. Mice were divided into two groups: 1) exposure to normal air (n=7) and 2) exposure to 
a mixture of 8% CS and normal air (n=7). The 8% CS/air mixture was obtained by smoking 
Kentucky 3R4F research cigarettes using a peristaltic pump (Watson-Marlow). Mice were 
exposed twice daily for 30 minutes (four cigarettes per session with three minutes normal air 
after each smoked cigarette) for 8 days in total. In parallel, control mice were exposed to 
normal air following the same schedule. During exposure, both groups of mice were placed 
in an air-sealed perspex box connected to an air-exhaust ventilator. The experimental design 
was approved by the ethical committee of animal welfare of our hospital.
The mice were weighed daily, and at day 8 anaesthetised with isoflurane/O2 and sacri-
ficed by heart puncture. Blood samples were collected to assess effective smoke exposure by 
measuring cotinine levels. Plasma samples were analysed with a certified liquid chromatog-
raphy and tandem mass spectrometry procedure (TSQ Quantum, Thermo Fisher Scientific, 
Wilmington, DE, USA) at the department of Hospital and Clinical Pharmacy of our hospital. 
For comparison, in humans a plasma cotinine level ≥15 µg/l is indicative of active smok-
ing.37 The colon was removed and the lumen was washed with PBS. Then the colon was 
divided into samples for qPCR, western blotting and immunohistochemistry, and immediately 
snap-frozen in liquid nitrogen or fixed with formaldehyde, respectively. Next, samples were 
stored at -80°C until further processing or embedded in paraffin for immunohistochemistry.
Human study
To examine whether cigarette smoke affects colonic HO-1 expression in humans, we exam-
ined HO-1 levels in colon biopsies of healthy smokers (n=9) and non-smokers (n=9) ob-
tained during colonoscopy. Non-smokers were defined as those who quitted smoking at least 
one year ago or never smoked. We excluded subjects: 1) on steroids, immunosuppression 
or omeprazole (the last is capable of inducing cytochrome P450 1A1 (CYP1A1))38,39, 2) after 
bowel resection, or 3) with abnormal findings other than diverticulosis, hyperplastic polyps 
or adenomas during colonoscopy, or with histological signs of inflammation. Characteristics 
of the participants are described in Table 1. All participants gave informed consent and the 
methods were approved by the medical ethics committee of our hospital.
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Thirty minutes before colonoscopy smokers smoked one Kentucky 3R4F research ciga-
rette. Just before colonoscopy, a venous blood sample was taken to measure carboxyhe-
moglobulin to confirm smoking status. Carboxyhemoglobulin was measured by the ABL800 
FLEX blood gas analyzer (Radiometer, Zoetermeer, The Netherlands). Reference values for 
non-smokers range from 0.5% to 1.5% (http://www.fk.cvz.nl). During colonoscopy biopsies 
were taken in the ascending colon, except in two subjects they were taken in the transverse 
colon. Two specimens for qPCR and western blotting were immediately snap-frozen in liquid 
nitrogen and stored at -80°C until further processing, and two specimens for immunohisto-
chemistry were fixed with formaldehyde and embedded in paraffin.
RNA isolation and quantitative polymerase chain reaction (qPCR)
For isolating RNA from DLD-1 cells and from colon samples of mice and humans, we used 
Trizol according to the manufacturer’s instructions. RNA content was quantified using Na-
noDrop 1000 spectrophotometer (Thermo Fisher Scientific). Reverse transcription and qPCR 
conditions were performed as described before.40 For qPCR we designed sense and anti-
sense primers and fluorogenic probes (Eurogentec, Herstal, Belgium) for HO-1, inducible 
nitric oxide synthase (iNOS), CYP1A1 and 18S using Primer Express 2.0 software (Applied 
Biosystems, Foster City, CA, USA). For primers and probes see supplementary Table 1. We 
performed qPCR for iNOS to exclude inflammation not detected by the pathologist, since 
iNOS expression is increased in inflammation.16 CYP1A1 is an enzyme involved in the me-
tabolism of a number of procarcinogens, including polycyclic aromatic hydrocarbons found 
in CS. Smokers had increased CYP1A1 activity in the duodenum,39 and therefore colonic 
CYP1A1 expression (qPCR) was studied as a positive control for exposure of the colon to CS. 
Fluorescence was measured using 7900 HT Fast RT-PCR System (Applied Biosystems). Each 
sample was analyzed in duplicate (ABI PRISM SDS 2.1 software, Applied Biosystems). Finally, 
the gene of interest was normalized to 18S (2-DCt method).
Table 1. Characteristics of  the healthy smokers and non-smokers
Smokers (n=9) Non-smokers (n=9)
Female/male 4/5 4/5
Median age (range)   44 (24-56) 49 (27-77)
Smoking behaviour:
  smoker
  former smoker







Median number of  years smoked (range) 30 (7-40)
Median number of  cigarettes/day (range) 17 (4-25)
Indication for colonoscopy:
  adenoma surveillance
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Western blot analysis
DLD-1 cells were lysed by four cycles of freeze-thawing (liquid nitrogen-37 °C). After ten min-
utes centrifugation at 13.000 g supernatant was collected. Colon specimens from mice and 
humans were homogenized in lysis buffer by 25 strokes with a plastic pestle and superna-
tant was obtained after ten minutes centrifugation at 13.000 g. Protein concentrations were 
measured using the BioRad DC protein assay (Bio-Rad, Veenendaal, The Netherlands).
For analyzing protein expression we performed western blots. Twenty microgram of pro-
tein was fractioned on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane 
(Hybond-ECL, Amersham Biosciences, GE Healthcare, Diegem, Belgium) by semi-dry blot-
ting. Membranes were stained with Ponceau-S for transfer control. Next, the membranes 
were blocked with 2% milk/0.5% BSA (ELK, Campina, Zaltbommel, The Netherlands) in 
PBS/0.1% Tween-20 (PBS-T, Sigma-Aldrich). For HO-1 detection we used a monoclonal 
antibody #OSA-110 (1:1000, StressGen, Victoria, British Columbia, Canada) as primary 
antibody. After washing with PBS-T, blots were incubated with the secondary antibody horse-
radish peroxidase-labeled goat anti-rabbit IgG (1:2000, Dako, Glostrup, Denmark). Blots 
were washed with PBS-T and finally with PBS, and developed by exposure to ECL substrate 
(SuperSignal West Dura, Pierce/Perbio Sciences, Etten-Leur, The Netherlands). Blots were 
stripped in PBS-T in 0.1% SDS at 65°C for 30 min and re-probed with a GAPDH antibody 
and used as loading control.
Immunohistochemistry analysis
Four µm thick slices were cut from colon tissue of mice and humans. For HO-1 detection 
antigen-retrieval was performed in EDTA-buffer at 300 Watt for 15 min in a microwave oven. 
Slides were incubated with an anti-HO-1 monoclonal antibody (1:200, #OSA-110, Stress-
Gen) as described before.16 Endogenous peroxidase was blocked with 0.3% hydrogen per-
oxide. Peroxidase-conjugated rabbit anti-mouse Ig and peroxidise-conjugated mouse anti-
rabbit were used as secondary and tertiary antibodies (both 1:50 in 1% BSA/PBS containing 
1% human serum, Dako). Colour was developed using 3-3-diaminobenzidine tetrahydro-
chloridehydrate. Slides were counter-stained with hematoxylin. Negative control stainings 
were performed by omitting the anti-HO-1 antibody. Images were taken with a Leica DM LB 
microscope (Leica, Wetzlar, Germany).
Statistical analysis
Descriptive variables are presented as medians (range) or as means (standard deviation), 
and categorical variables as frequencies with percentages. Differences between groups were 
compared with the Mann-Whitney U-test. A p-value <0.05 was considered statistically sig-
nificant. The data were analyzed using GraphPad Prism 5.00 software (GraphPad software, 
San Diego, CA, USA).
Results
Effect of  cigarette smoke (CS) on HO-1 expression in DLD-1 cells
First, we studied the effects of CSE on colonic HO-1 expression in vitro. CSE dose-depend-
ently induced HO-1 mRNA levels in DLD-1 cells, from 1.6-fold at 5% CSE to 80-fold at 
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30% CSE (Figure 1A). CSE also dose-dependently induced HO-1 protein expression as 
determined by Western blot analysis (Figure 1B). Summarizing, CS increased colonic HO-1 
expression in vitro.
Effect of  cigarette smoke on colonic HO-1 expression in mice
Second, we studied the effects of CS on colonic HO-1 expression in mice. Analysis of the 
blood samples revealed a median cotinine level of 65 µg/l (range 45-112 µg/l) in mice ex-
posed to CS and <5µg/l in control mice. In contrast to our hypothesis, colonic HO-1 mRNA 
levels were equal between mice exposed to normal air and to CS (Figure 2). No significant 
amounts of HO-1 were detected by Western blotting and immunohistochemistry, confirming 
the findings by qPCR (data not shown). Clinically, we observed no difference in body weight 
between mice exposed to normal air and to CS. The iNOS mRNA levels were equal between 
both groups of mice, implying no differences in colonic inflammation (data not shown). Sum-
marizing, cotinine levels were high in mice exposed to CS, but CS had no effect on colonic 
HO-1 expression in mice.
Effect of  cigarette smoke on colonic HO-1 expression in humans
Third, we studied the effects of CS on colonic HO-1 expression in humans. Nine smokers 
with median smoking time of 30 years and smoking intensity of median 17 cigarettes per 
day were compared to nine non-smokers (Table 1). In non-smokers median carboxyhemo-





























    CSE 0%       CSE 5%       CSE 10%     CSE 20%     CSE 30%
Figure 1B. 
Figure 1. (A) Heme oxygenase 1 (HO-1) mRNA expression levels in DLD-1 cells incubated with cigarette 
smoke extract (CSE) 0, 5, 10, 20 or 30% for 9 h.  The HO-1 mRNA expression was normalized to the 
expression of  18S. CSE dose-dependently induced HO-1 mRNA levels. Data are presented as mean of  
three independent experiments ± SD. (B) A representative Western blot of  HO-1 protein expression in 
DLD-1 cells incubated with CSE 0, 5, 10, 20 or 30% for 9 h. GAPDH is used as internal control. CSE 
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colonoscopy. In line with our findings observed in mice, levels of colonic HO-1 mRNA were 
equal between healthy non-smokers and smokers (Figure 3A). HO-1 protein expression on 
Western blot was very low in both smokers and non-smokers (data not shown). Immunohis-
tochemistry was in line with the findings on mRNA level, with no differences in HO-1 stain-
ing between non-smokers and smokers (Figure 3B). HO-1 staining was mainly localized in 
epithelial cells, and in a few inflammatory cells. Summarizing, we found no effects of CS on 
colonic HO-1 expression in humans.
Effect of  cigarette smoke on colonic CYP1A1 expression
Finally, we studied the effects of CS on colonic CYP1A1 expression as a positive control for 
exposure of the colon to CS. We examined the colonic CYP1A1 mRNA expression in vitro, 
in mice and in humans exposed to CS. In DLD-1 cells exposed to CSE a dose-dependent 
induction of CYP1A1 mRNA levels was observed (Figure 4A). The highest up-regulation was 
seen with 10% (1198-fold) and 20% (991-fold) CSE. In mice exposed to CS (Figure 4B) and 
in smoking humans (Figure 4C) CYP1A1 mRNA expression was also increased (7-fold and 
26-fold, respectively) compared to subjects not exposed to CS. Summarizing, CS increased 



























Figure 2. Figure 2. Colonic heme oxygenase 1 (HO-1) mRNA expression levels in mice exposed to normal air (con-
trols) and to cigarette smoke for eight days. The HO-1 mRNA expression was normalized to the expression 
of  18S. HO-1 mRNA levels were equal between mice exposed to normal air and to cigarette smoke. Data 






























































Figure 3. (A) Heme oxygenase 1 (HO-1) mRNA expression levels in colon biopsies of  human non-smokers 
and smokers. The HO-1 mRNA expression was normalized to the expression of  18S. HO-1 mRNA levels 
were equal between non-smokers and smokers. Data are expressed as mean (n=9 and 10) ± SD. (B) Immu-
nohistochemistry for HO-1 in colon biopsies of  human non-smokers (i: 200x) and smokers (ii: 200x). Stain-
ing of  HO-1 (arrows) is mainly localized in the epithelial cells on the surface, and in a few inflammatory 






























































































Figure 4. Cytochrome P450 1A1 (CYP1A1) mRNA expression levels in (A) DLD-1 cells incubated with 
cigarette smoke extract (CSE 0, 5, 10, 20 or 30%) for 9 h, (B) colons of  mice exposed to normal air (con-
trols) and to cigarette smoke for eight days, and (C) colon biopsies of  human non-smokers and smokers. 
The CYP1A1 mRNA expression was normalized to the expression of  18S. CYP1A1 mRNA levels were 
increased in DLD-1 cells, mice and humans exposed to cigarette smoke. Data are expressed as mean ± SD. 
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Discussion
Smoking has beneficial effects on UC, but the pathways influenced by CS are unknown. Two 
findings suggest the putative involvement of the HO-1 pathway. First, induction of HO-1 
was beneficial in animal models of intestinal injury.22-27 Second, cigarette smoke is able to 
induce HO-1 in several different human cells and tissues.30,31,33-36 However, the effect of CS 
on intestinal epithelial cells was so far unknown. Therefore, we studied the effects of CS on 
colonic HO-1 in vitro, in mice and in humans. In the animal experiments plasma cotinine 
levels were highly indicative of active smoking and in the human experiments smoking ex-
posure was proven by measuring carboxyhemoglobulin levels. In addition, the number of 
cigarettes smoked by our study objects (median 17 per day) is in the therapeutic range of 
UC, since the studies with a positive effect of smoking on UC had a median number of ciga-
rettes comparable or lower than 17 cigarettes per day.5-7 We hypothesized that CS increases 
the colonic expression of HO-1, implying that the beneficial effect of smoking in UC could 
act through the HO-1 pathway. However, our findings did not support our hypothesis. CSE 
induced HO-1 in vitro, but there were no differences in HO-1 expression between smokers 
and non-smokers in mice and humans.
The beneficial effects of HO-1 on colitis have been studied by different approaches. Paul et 
al. studied the effects of HO-1 induction on an experimental colitis model in mice and showed 
that induction before the onset of inflammation led to reduced colonic inflammation.26 These 
results suggested a protective effect of HO-1 induction on the development of colitis, which 
is in line with the beneficial effect of smoking on the development of UC.1-5 However, HO-1 
induction after the onset of acute colitis or during chronic colitis was not effective and they 
concluded that induction of HO-1 may not be a promising approach in chronic UC.26 This is 
not in line with the beneficial effects of smoking on UC after diagnosis.5-10
Previously, we studied the regulation and interaction of HO-1 and iNOS in response to oxi-
dative stress and inflammation in vitro and in rats.16 Oxidative stress induced HO-1 in intesti-
nal epithelial and inflammatory cells, but prevented iNOS induction in an NF-κB-dependent 
manner. Inflammation caused by a cytokine mixture of IL-1β, IFN-γ and TNF-α induced 
iNOS, but not HO-1. Furthermore, the HO-1 end-product CO inhibited the cytokine mixture 
induced iNOS expression. These data demonstrated opposite regulation of HO-1 and iNOS 
in intestinal epithelial cells in response to oxidative stress and cytokine exposure, suggesting 
that HO-1 (activator protein-1 driven) and iNOS (NF-κB driven) represent mutually exclusive 
survival mechanisms in intestinal epithelial cells.
The intestinal HO-1 expression in patients with UC has also been studied. HO-1 ex-
pression was increased in active UC compared to inactive disease and healthy controls.41 
Another study showed increased HO-1 expression in patients with UC and other conditions 
of chronic intestinal inflammation as Crohn’s disease, intestinal ischemia and diverticulitis.26 
Finally, intestinal HO-1 expression was increased in biopsies from inflamed colon in UC pa-
tients compared to colon biopsies from normal mucosa of subjects with colon cancer.42 No 
clear consensus is present about the cell type-specific expression of HO-1 in the intestinal 
mucosa. Two studies showed HO-1 staining in both inflammatory and epithelial cells,26,41 
but in a recent study no significant amounts of HO-1 were detected in epithelial cells.42 In 
contrast, we found HO-1 staining in normal mucosa predominantly in epithelial cells, and 
in a few inflammatory cells.
Our data exclude a local effect of smoking on intestinal HO-1, since we found no dif-
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ferences in intestinal HO-1 expression between smokers and non-smokers. Nevertheless, 
smoking is able to trigger other protective processes localized in the colon, since we ob-
served that smoking inhaled via the lungs finally reaches the colon and increases the expres-
sion of colonic CYP1A1 in smokers compared to non-smokers. Still, our findings do not fully 
exclude an interaction between smoking and the HO-1 pathway as being beneficial for UC 
patients. Smoking could act its beneficial effects on UC through a systemic up-regulation of 
HO-1. Healthy smokers have increased HO-1 expression in the lungs33 and in the gingival 
tissue34 leading to an increase in the anti-oxidative, anti-apoptotic and anti-inflammatory 
end-products biliverdin, Fe2+ and CO.11-17 Especially the beneficial role of CO seems prom-
ising. Exposure to CO ameliorated chronic colitis in mice24 and protected the transplanted 
intestine against cold ischemia/reperfusion injury in rats.43 Since smoking causes chronic 
exposure to CO,14,17 smoking could also exert its beneficial role in UC directly via CO and 
thus independent of HO-1.
It is important to note the putative limitations of our study. The mouse model for studying 
the effects of smoking may not be a good model for active smoking. Whole body exposure 
is actually more a model for passive smoking. However, this model is less stressful for mice 
than the nose-only exposure model (active smoking), where mice are put in strains and are 
not able to move. Furthermore, the increased colonic CYP1A1 expression in the smoke-
exposed mice shows that smoke was inhaled and reached the bowel, and the high cotinine 
levels (median 65 µg/l) indicate active exposure to CS, since in humans heavy exposure to 
passive smoking rarely results in cotinine levels >10 µg/l.44 Another limitation is that we used 
for qPCR and western blotting in mice the whole colon, including the muscle layer, instead of 
a scraping of the mucosa. This could have caused a dilution of HO-1 expression.
In conclusion, although smoking induced HO-1 expression in colonic cells in vitro, no 
effect of smoking on in vivo colonic HO-1 expression in humans and mice was shown. So 
smoking does not exert its beneficial effect on UC via up-regulation of colonic HO-1. How-
ever, smoking could exert its beneficial effects on UC through an up-regulation of HO-1 in 
the lungs causing increased carboxyhemoglobulin levels. CS does induce colonic CYP1A1 
expression which indicates that CS is able to trigger other protective mechanisms locally in 
the colon.
Smoking and colonic heme oxygenase 1
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Long-term morbidity and survival after orthotopic liver transplantation (OLT) are for a main 
part determined by cardiovascular disease and cancer. Tobacco use is a well-known risk fac-
tor for both. The aim of this study was to examine smoking behaviour before and after OLT, 
and to define groups at risk for resuming tobacco use after OLT. In addition, we looked for 
a relation between smoking and morbidity after OLT. 
Methods: 
All 401 adult patients with a follow-up of at least 2 years after OLT were included. Data were 
collected from the charts. A questionnaire about smoking habits at four time points before 
and after OLT was sent to all 326 patients alive, and 301 (92%) patients responded. 
Results: 
Both before and after OLT, 53% of patients never used tobacco and around 17% were active 
smokers. Of the active smokers during the evaluation for OLT almost one third succeeded in 
cessation, often during the waiting time for OLT. Twelve percent of former smokers restarted 
smoking, mainly after OLT. Tobacco use was the highest in patients with alcoholic liver dis-
ease (52% active smokers before OLT, 44% after OLT), and the lowest in primary sclerosing 
cholangitis (1.4% active smokers before OLT). At 10 years the cumulative rate of malignan-
cies was 12.7% in active smokers compared to 2.1% in non-smokers (p=0.019). No effect 
on skin cancer or cardiovascular disease was found. 
Conclusion: 
Smoking is a serious problem after OLT and increases the risk for malignancy. Prevention 
programs should not only focus on active smokers, but also on former smokers.
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Introduction
Orthotopic liver transplantation (OLT) is an accepted therapy for end-stage liver disease. 
The last decades short term survival after transplantation has improved with nowadays a 
one year survival rate of 85% and a five year survival of 75% (http://www.optn.org). Besides 
recurrence of the primary disease, the main causes of death in liver recipients on the long 
term are cardiovascular events and malignancies.1-6 Therefore it becomes more and more 
important to prevent diseases and health problems that are not associated with the original 
liver disease. Smoking is an important risk factor for cardiovascular events as well as for 
several malignancies. Smoking is considered one of the leading causes of preventable death 
in the general population and could also be an important one in liver transplant recipients. 
However, studies about the smoking behaviour of liver transplant recipients are scarce. Di-
Martini et al. have prospectively studied the smoking behaviour in patients transplanted for 
alcoholic liver disease (ALD) and they found that recipients resume smoking early after OLT 
and increase consumption over time.7 Ehlers et al. reported 15% active smokers after OLT 
and a relapse rate of 20% in former smokers.8 Both studies were performed in the United 
States. 
Studies on the effects of smoking on the long-term course after OLT are also scarce. Some 
studies have reported a possible relation between smoking and malignancies after OLT,9,10 
especially in recipients with ALD.11-13 In a previous study from our group, a relation between 
smoking and cardiovascular events was suggested in a group of 331 OLT recipients.6 In 
recipients of other solid organ transplants much more studies on the effects of smoking have 
been performed. These showed that tobacco use was associated with graft loss and mortality 
in renal transplant patients,14,15 graft loss in pancreas transplant patients,16 cardiovascular 
disease in renal transplant patients,14,17-19 and malignancies in renal,20 lung,21 and heart 
transplant patients.22 
The primary aim of the present study was to examine smoking behaviour before and after 
OLT, and to look for patient groups at risk for resuming smoking after OLT. In addition we 
looked for a relation between smoking and survival and morbidity after OLT.
Methods 
Patients
All adult patients who had undergone liver transplantation in our hospital between 1979 and 
May 2005, and had a follow-up of at least two years after transplantation were included. 
Patient characteristics, pretransplant malignancies (including skin) and cardiovascular sta-
tus, and the outcome variables were obtained through retrospective analysis of the medical 
charts. The immunosuppression protocol has been described before.23,24 Briefly, patients 
transplanted between 1979 and 1986 received azathioprine and steroids. After 1986 cy-
closporine was added, and after 1997 patients received a calcineurin-inhibitor (cyclosporine 
or tacrolimus) and steroids, with or without azathioprine. Some patients used sirolimus be-
cause of renal dysfunction.
Smoking after liver transplantation
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Smoking behaviour
Data on smoking behaviour were collected in two ways. First, retrospectively from the medi-
cal charts, and second, by a questionnaire. From the charts we collected data at four time 
points: during evaluation for OLT (before listing), shortly before OLT, 2 years after OLT, 
and at the end of follow-up. At each time point it was determined if a patient was an active 
smoker, a former smoker, or a never smoker. A questionnaire was sent to all patients pres-
ently alive. In this questionnaire the patients were asked about their smoking habits at the 
four time points mentioned above. Of each time point it was asked if the patient was an 
active smoker, a former smoker, or a never smoker. In addition, questions were included on 
number of years of tobacco use, and, in case of a former smoker, when tobacco use was 
stopped, on type of tobacco product, on average number of cigarettes or otherwise per day, 
and on plans for smoking cessation and willingness to participate in a free smoking cessation 
course in our hospital. Smokers were defined as smoking seven or more cigarettes per week. 
For converting cigars to cigarettes we equated one cigar with four cigarettes, considering that 
an average cigar contains four grams and one cigarette one gram of tobacco.25 
Pretransplant cardiovascular status and outcome variables
For pretransplant cardiovascular status we recorded treatment for diabetes mellitus and hy-
pertension, and vascular events (angina pectoris, myocardial infarction, coronary interven-
tions, transient ischemic attack, cerebral vascular accident, intermittent claudication and 
intervention for large vessel disease).    
For outcome variables we looked at patient and graft survival, occurrence of hepatic artery 
thrombosis, de novo malignancies and de novo vascular events. For graft survival we re-
corded need and reason for retransplantation. Date was noted of all events and events were 
recorded till the end of follow-up, May 2007.
Ethical considerations
The methods used were discussed with the medical ethics committee. According to Dutch 
legislation there were no objections against the methods used. A returned questionnaire was 
considered as an informed consent.
Statistical analysis
Categorical variables are presented as frequencies with percentages and continuous vari-
ables as medians (range). The data were analyzed using the Statistical Package for the Social 
Sciences program version 14.0 (SPSS Inc., Chicago, Illinois, USA). Categorical variables 
were compared with the chi-square test and continuous variables with the Mann-Whitney 
test. Outcome variables were tested for significance by using the Kaplan-Meier method, with 
the log rank test. Differences are considered significant when p ≤ 0.05. 
Results   
Clinical Characteristics
In our hospital 867 liver transplantations were performed between 1979 and May 2005. 
Of these, 526 were adult patients undergoing at least one liver transplant. Eleven patients 
7111
were lost to follow-up (6 living outside the Netherlands, 3 with follow-up elsewhere and 2 
unknown) and of the remaining 515 recipients, 401 (78%) survived at least two years after 
transplantation and these were included in the present study. Clinical characteristics of the 
401 recipients are shown in Table 1. At the time of this study 326 patients were alive and 75 
were deceased. The most frequent indications for transplantation were primary sclerosing 
cholangitis (PSC) and primary biliary cirrhosis. 
Smoking behaviour according to questionnaire
Three hundred and one of the 326 patients returned the questionnaire, a response rate of 
92%. Next and in Figures 1-4 the results are presented at the time points evaluation for OLT, 
at time of OLT, 2 years after OLT, and at the end of follow-up (a median 8.6 (range 2-26) 
years after OLT).
Table 1.  Patient characteristics






Female gender 208 (51.9) 164 (50.3) 44 (58.7)
Age at OLT (yrs, median, range) 46.5 (18.1-67.7) 45.7 (18.1-67.7) 50.3 (22.6-62.4)
Date of  OLT (median, range) Aug, 1997 (Apr, 
1979-May, 2005)
Aug, 1998 (Apr, 
1979-May, 2005)
Sep, 1993 (Oct, 
1979-Nov, 2003)
Follow-up after OLT (yrs)
    (median, range)









Diagnosis (no of  pts, %)
    Primary sclerosing cholangitis
    Primary biliary cirrhosis
    Viral (Hepatitis B and/or C)
    Metabolic disease 
    Cryptogenic cirrhosis 
    Alcoholic cirrhosis
    Autoimmune cirrhosis
    Acute liver failure 




























Malignancy in explant (no of  pts, %)
    Hepatocellular carcinoma










Immunosuppresion 1 year after OLT
    Cyclosporine/tacrolimus/sirolimus
    Azathioprine/mycophenolate mofetil











    Cyclosporine/tacrolimus/sirolimus
    Azathioprine/mycophenolate mofetil










Abbreviations: OLT, orthotopic liver transplantation; SD, standard deviation.
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Smoking behaviour
Both before and after OLT a majority of patients never smoked (53-54%). About a third of 
the patients were former smokers (28-32%) and a substantial minority of 14-18% was ac-
tive smoker. In Figure 1 it is shown that at the several time points the percentages are rather 
stable, with only a small decline in active smokers shortly before OLT. 
Smoking behaviour of never smokers. In Figure 2 it is shown that of the 163 patients who 
had never smoked at the time of evaluation, most refrained from smoking, with only 2.5% of 
the patients smoking at two years after OLT and 1.8% at the end of follow-up.
Smoking behaviour of former smokers. In Figure 2 it is shown that of the 85 patients who 
were former smokers at the time of evaluation, most refrained from smoking until OLT, but 
up to 12% restarted smoking after OLT. The 10 patients that relapsed after OLT had stopped 
smoking at a median of 10 months (1-36) before OLT. The 75 former smokers that did not 
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Figure 2. 
Figure 1. Smoking 
behaviour of  the 
respondents to the 
questionnaire before 
and after OLT 
(n=301). Abbreviations: 
FU, follow-up; OLT, 
orthotopic liver 
transplantation.
Figure 2. Course of  
smoking behaviour 
after evaluation for 
never smokers, former 





significant (p<0.001). Figure 3 shows in more detail that a minority of patients restarted 
smoking and later stopped again.
Smoking behaviour of active smokers. In Figure 2 it is shown that of the 53 active smok-
ers at the time of evaluation, 26% succeeded in quitting of smoking before OLT, and this 
remained and even increased a little to 32% after OLT. But these are overall percentages. 
Figure 4 shows in more detail that a minority of these 53 patients first stopped, but later 
restarted smoking at some time after OLT, and sometimes stopped again later. At 2 years 
after OLT there were 50 active smokers, including (re)starters, and 20% succeeded in quitting 
smoking at the end of follow-up. 
Relation between smoking and patient characteristics. 
No relation was found between smoking and gender, and between smoking and age in 
smokers and never smokers. Former smokers at evaluation were older than never smokers 
At evaluation 
85
2  38 
2 0 7 76 
1 1 5 2 4 72 
At OLT 
2 years after OLT 
End of follow up
Figure 3. 
53
39  41 
32 7 5 9 
28 34 4 3 2 2 7 
2 years after OLT 
At OLT 
At evaluation 




2  38 
2 0 7 76 
1 1 5 2 4 72 
t OLT 
2 years after OLT 
End of follow up
Figure 3. 
53
39  41 
32 7 5 9 
28 34 4 3 2 2 7 
2 years after OLT 
t OLT 
At evaluation 
End of follow up
Figure 4. 
Figure 3. Former smokers at evaluation for OLT and changes in behaviour afterwards. The underlined 
numbers indicate the number of  active smokers; the other numbers indicate the number of  former smokers. 
Abbreviation: OLT, orthotopic liver transplantation.
i re . Active smokers at evaluation for OLT and changes in behaviour afterwards. The underlined 
numbers indicate the number of  active smokers; the other numbers indicate the number of  former smokers. 
Abbreviation: OLT, orthotopic liver transplantation.
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(median 51.2 years vs 42.9 years; p=0.001) and active smokers (median 51.2 years vs 
45.9 years; p=0.05). At the time of evaluation for OLT, more patients with ALD and with 
acute liver failure were active smokers (respectively 52 and 46%) compared to the other 
diagnoses (see Figure 5, p<0.001). In this respect the percentage of active smokers in the 
group with PSC was the lowest (1.4%). In the alcoholic group, only 8% were never smokers, 
whereas 77% of PSC patients had never smoked at the time of evaluation (Figure 5). At the 
end of follow-up the same pattern was seen with 44% active smokers in the alcoholic group, 
and only 4.3% in the PSC group (p<0.001). The number of active smokers (31%) in the 
acute liver failure group was not different anymore compared to the other diagnoses.
Smoking was also studied in ALD patients with respect to relapse into drinking. Of the 25 
patients with alcoholic cirrhosis only six had one or more relapses into drinking after OLT, 
with one patient persistently drinking. Of the six relapsers, four were smokers at the end of 
follow-up (67%), one was a former smoker (17%) and one had never smoked (17%). Of the 
19 nonrelapsers seven patients were smokers at the end of follow-up (37%), 11 were former 
smokers (58%) and one had never smoked (5%). There was a tendency for a lower number 
of former smokers in the relapsers compared to the nonrelapsers (p=0.078).
Smoking characteristics
Both before and after OLT, and in both active and former smokers, the large majority of 
patients smoked only cigarettes and/or hand-rolling tobacco (92% and 86% respectively). 
A minority preferred pipe and/or cigars (about 5%). No statistical differences between the 
different groups and time points were found in this respect. 
At the end of follow-up, the then active smokers had smoked a median of 34 years (range 
2-50), and they reported smoking a median of 11 cigarettes per day (range 2-60). At the end 
of follow-up the then former smokers had smoked a median of 15 years (range 3-45), and 
they reported smoking a median of 10 cigarettes per day (range 1-45). The former smokers 































































































57           50          27          13 Number of mokers at risk           
225           170          89          23 Number of nonsmokers at risk
Figure 6. 
Years after OLT
Figure 5. Smoking behaviour during evaluation for orthotopic liver transplantation according to primary 
liver disease. Abbreviations: HBV, Hepatitis B virus; HCV, Hepatitis C virus; PBC, primary biliary cirrhosis; 
PSC, primary sclerosing cholangitis.
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Smoking cessation plans
In the questionnaire, the still smoking patients were asked about plans to quit smoking. Five of 
the 49 patients did not answer this item. Of the other 44 patients, 20 patients (45%) wanted to 
stop within six months, 7 (16%) within five years, 10 (23%) ever and 7 (16%) never. When offered 
to join a cost-free smoking cessation course, four of the 49 patients did not answer this item. Of 
the other 45 patients, 6 patients accepted the offer (13%), 28 (62%) refused and 11 (24%) were 
in doubt. For the intenders to stop smoking within 6 months, 30% accepted the offer.
Relation between smoking and outcome after liver transplantation
Relation to patient and graft survival
For the analysis of the effect of smoking on patient and graft survival, we first had to make a 
comparison between smoking behaviour data acquired from the charts and those acquired 
from the questionnaires. The charts turned out to be incomplete in detail. Comparison could 
be made however with respect to active smoking at the different time points before and after 
transplantation, and with respect to ever having smoked before or after liver transplantation. 
As is shown in Table 2 active smoking is underestimated in the charts, with up to one third 
less active smokers in the charts compared to the questionnaires. The same was true for ever 
smoking data, except for the time after OLT. In both the charts and the questionnaires 22% of 
patients ever smoked after OLT. 
Based on this analysis, patient and graft survival were studied comparing patients of whom 
the charts mentioned smoking in the post-transplant period versus those of whom the charts 
mentioned no smoking or unknown. In the group of 401 patients no differences were found 
for patient and graft survival between the 103 ever smokers after OLT and the other 298 
patients. Also after exclusion of the 59 patients with unknown behaviour, there were no differ-
ences in patient and graft survival between ever smokers and nonsmokers. Furthermore, no 
differences were found for the causes of graft failure between smokers and the other patients. 
Overall patient survival at one year was 100% (inclusion criterion), at five years 93%, at ten 
years 85%, at fifteen years 72% and at twenty years 64%. Overall graft survival at one year 
was 93%, at five years 82%, at ten years 73%, at fifteen years 60% and at twenty years 49%.
Table 2. Tobacco use from medical charts versus questionnaires
Characteristic: n (%)  Medical charts Questionnaire
Patients 301 301
Active smokers:
   Evaluation
   At OLT
   2 years after OLT  










   Ever  
   Pre OLT







Abbreviation. OLT, orthotopic liver transplantation.
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Relation to morbidity
Because of lack of detail in the charts with respect to smoking behaviour, we decided to 
study the possible relation between smoking and post-transplant morbidity only in the group 
of responders to the questionnaire. Fifty nine responders who reported tobacco use at two 
years after OLT and/or at the end of follow-up were compared with 236 responders who 
reported to have abstained from tobacco use after OLT. The comparison is shown in Table 
3. De novo malignancy, excluding skin cancer, developed significantly more often in smokers 
compared to nonsmokers (see Figure 6; p=0.019, Kaplan-Meier log rank test). The cumula-
tive risk (standard error in brackets) for development of de novo malignancy in smokers was 
3.5 (2.4), 12.7 (4.9), and 18.2 (7.0)% at 5, 10, and 15 years after OLT, respectively. In non-
smokers this was 0.6 (0.6), 2.1 (1.2), and 7.7 (3.8)%, respectively. Tumor types in smokers 
were oropharynx cancer (1 patient), cancer of the vulva or cervix (2 patients), colon cancer 
(2 patients), and post-transplant lymphoproliferative disorder (2 patients). Tumor types in 
nonsmokers were gastric, colon, and prostate cancer (1 patient each), post-transplant lym-
phoproliferative disorder (2 patients), and de novo hepatocellular carcinoma (1 patient). We 
found a tendency for hepatic artery thrombosis occurring more often in smokers compared 
to nonsmokers (p=0.078, Kaplan-Meier log rank test).
Table 3. Outcome for posttransplant active smokers and nonsmokers
Characteristic: n (%) Smokers (n = 59) Never smokers 
(n = 236)
  Retransplantation 
  Hepatic artery thrombosis
  Cardiovascular events de novo
  Hypertension de novo
  Diabetes mellitus de novo
  Malignancies (including skin) de novo 
  Malignancies (excluding skin) de novo
















































































































57           50          27          13 Number of smokers at risk           
225           170          89          23 Number of nonsmokers at risk
Figure 6. 
Years after OLT
Figure 6. Cumulative 
risk of  de novo nonskin 
malignancies between 
smokers and nonsmokers 
after OLT. Abbreviation: 




Long-term morbidity and survival after OLT are determined for a main part by the develop-
ment of cardiovascular diseases and cancer. Tobacco use is a well-known risk factor for both 
disease entities. In our country tobacco use is increasingly forbidden in public areas, but until 
July 1, 2008, smoking was still allowed in restaurants and bars. In our center discontinuation 
of tobacco use is encouraged before the actual transplant takes place, but is not a contrain-
dication. The present study gives us insight into the smoking patterns and some negative 
effects of smoking. In addition, the study helps to recognize subgroups of patients who could 
be offered extra help in the future.
As we were mainly concerned with long term negative effects of smoking, we studied pa-
tients who survived at least 2 years after OLT. Detailed data were not available in the medical 
charts; therefore we used a questionnaire which was sent to all patients alive. The response 
rate was high (92%). Although this method has several drawbacks, including a recall bias of 
events that took place in the past, the facts that the questionnaires remained anonymous to 
the treating physicians and were sent several years after sofar successful transplantation must 
have helped the patients to report the truth. 
Both before and after OLT a small majority of patients had never used tobacco and around 
17% of the patients were active smokers. This figure compares favourable with the Dutch 
population as in 2007 28% of the Dutch population were reported to be active smokers 
(Dutch central agency for statistics; http://statline.cbs.nl). The percentage active smokers in a 
German population of kidney transplants was 13%,26 and in Italian heart transplants 12%.27 
A positive finding was that of the patients that smoked at the time of the evaluation for OLT, 
almost one third succeeded in smoking cessation, often during the waiting time for OLT, 
although sometimes with ups and downs (Figures 2 and 4). That the overall percentage of 
active smokers before and after OLT were about the same implies that other patients, mainly 
former smokers at the time of evaluation (12%), restarted smoking after OLT (Figures 2 and 
3). We found that especially former smokers who had succeeded in stopping tobacco use a 
relatively short time ago were at risk for a relapse.
To the best of our knowledge, there is only one study in liver transplant patients reported 
in the literature that is comparable to our study. Ehlers et al. studied patients transplanted in 
Florida.8 Their method was a structured interview by telephone with a 42% response rate. 
They reported 15% active smokers after OLT and a relapse rate of 20% in former smokers. 
Both figures are comparable with our findings. However, the response rate of 42% makes 
the possibility of an underestimation higher than in our study with a response rate of 92%, 
and therefore comparison of the data remains problematic. From both studies it follows that 
intervention programs should not only be aimed at active smokers, but also at former smok-
ers, and that these programs should be continued for many years, if not life long.
We found that most former smokers started smoking early in their life and quitted after a 
median 15 years of smoking, long before transplantation. The range was wide however. At 
the end of follow-up the cumulative number of smoking years was twice as high in the active 
smokers compared to the former smokers. It was no surprise that almost all patients used 
tobacco by smoking cigarettes and/or hand-rolling tobacco. Pipes or cigars were enjoyed 
by only 5% of the patients.
Tobacco use was highest in patients with ALD and in those with acute liver failure. During 
evaluation 52% of the alcoholic group were active smokers (and only 8% never smokers). 
Smoking after liver transplantation
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The combination of alcohol and tobacco addiction is well known and has been reported to 
be as high as 90% in alcohol abusers.28,29 This combination is also shown in our finding of 
a tendency for a higher number of former smokers in ALD patients without a relapse into 
drinking, which suggests that nonrelapsers are more likely to stop smoking than relapsers. 
As alcohol abstinence for at least six months was a prerequisite for OLT in our center, it is 
disturbing that still so many continued active smoking. At the end of follow-up active smoking 
in this group had decreased from 52% to 44%; this decrease is remarkable when compared 
to the whole group (18% to 16%). Probably there is already more attention for this group of 
patients or attention to stop alcohol use also influences smoking behaviour, but clearly more 
is needed to further bring down these figures. DiMartini et al. from Pittsburgh mentioned to-
bacco use after OLT for alcoholic liver disease an underestimated problem as these patients 
were reported to have a high incidence of lung and pharyngeal cancer.7,30-32 They found that 
on average more than 40% of patients with ALD were smoking after OLT and that smoking 
was resumed already at 3 months post-OLT. Our data seem comparable, except that we 
show an overall decrease if reckoned from evaluation for OLT onwards.7 
Remarkable is the PSC group with only 1.4% active smokers and 77% never smokers at 
the time of evaluation for OLT. A possible protective effect of smoking on the development 
of PSC33-36 and ulcerative colitis37-39 has been shown before. The exact protective mechanism 
of smoking is not yet known. Studies with nicotine as therapy for PSC showed no beneficial 
effects.40,41 It would be interesting to study the effects of smoking on recurrent PSC after OLT, 
but because of the low number of tobacco users in this patient group, this will only be pos-
sible in a multicenter study group.
We did not find a negative effect of active smoking after OLT on long-term patient and 
graft survival sofar, but this item could be studied only with smoking data from the medical 
charts, and these data were incomplete. However, in the group of survivors who responded 
to the questionnaire, we did find that the prevalence of nonskin cancer was significantly in-
creased in active smokers after OLT. At ten years the cumulative malignancy rate was 12.7% 
in smokers compared to 2.1% in non-smokers after OLT. Malignancies seemed to develop 
much earlier after OLT in tobacco users (Figure 6). We did not notice a difference in types of 
tumors that developed. Also no effect on skin cancer was found. Tobacco use as a risk factor 
for malignancy after OLT has been recognized before.9-13 Previous studies however relied on 
data in medical charts and most often not on actual posttransplant smoking data.
We did not find an increased prevalence of cardiovascular disease in smokers. Most likely 
tobacco use is only one of the many risk factors for cardiovascular disease after OLT, such as 
overweight, diabetes, hypertension, and the use of immunosuppressive agents.
In summary, both before and after OLT about 17% of patients are active smokers, but after 
OLT this percentage includes restarting former smokers and a decreasing number of actively 
smoking ALD patients. Proportionally, most tobacco users are found in the ALD group, and 
least in the PSC group. Pretransplant intervention programs should be aimed not only on 
pretransplant active smokers, but also on former smokers, especially those who stopped 
smoking quite recently. The higher prevalence of malignancies in active smokers after OLT 
warrants intervention programs after OLT and regular screening for malignancies.
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Summary
Two important groups of patients for the gastroenterologist and hepatologist are patients 
with inflammatory bowel diseases (IBDs) and liver diseases. The two most common IBDs 
are Crohn’s disease (CD) and ulcerative colitis (UC), and they are characterized by relaps-
ing inflammation of the gastrointestinal tract. In CD the entire gastrointestinal tract can be 
involved, while in UC the inflammation is limited to the colon. Another remarkable difference 
between CD and UC is the opposite effect of smoking. Smoking seems detrimental for CD, 
but beneficial for UC. Probably due to this remarkable opposite effect, smoking is a widely 
studied factor in IBD. The role of active smoking on the development of IBD is clear; smok-
ing is a risk factor for developing CD, but protective for UC. The role of passive smoking on 
the development of IBD is not clear. Studies on the effects of active smoking on the disease 
course of CD and UC are inconclusive; several studies showed detrimental effects on the 
course of CD and beneficial effects on UC, but for both diseases other studies could not 
confirm this. Finally, the role of passive smoking on the course of CD and UC is unknown.
It is unknown why smoking is detrimental for CD and beneficial for UC. Mechanisms 
that could be involved are the Toll-like receptor-4-dependent pathway in macrophages, the 
heme-oxygenase-1 (HO-1) pathway and thrombogenic effects of tobacco on the intestinal 
microvasculature. The understanding of the mechanism is complicated by the large number 
of components in cigarette smoke. Nicotine and carbon monoxide are the most studied com-
ponents, and both have detrimental and beneficial effects on intestinal inflammation.
The other important group is patients with liver diseases. Orthotopic liver transplantation 
(OLT) is an accepted therapy for end-stage liver disease. The prognosis of recipients has 
increased over the last decades. The most important causes of morbidity and mortality after 
OLT are malignancies and cardiovascular diseases. Smoking is a notorious risk factor for 
several malignancies and cardiovascular diseases in the general population, but studies 
about the role of smoking in recipients of liver transplants are scarce. The few reports avail-
able about the effects of smoking on OLT recipients show that smoking is a risk factor for 
several complications and serious events after OLT. However, literature on smoking behav-
iour in recipients is disappointingly scarce.
This thesis focuses on the role of active and passive smoking in IBD, and on the role of 
smoking in OLT recipients.
Chapter 1 starts with an introduction on the role of smoking in IBD and in OLT recipients, and 
describes the aims and outlines of the thesis.
In view of the opposite effect of smoking on CD and UC, different changes in smoking 
behaviour after diagnosis between CD and UC patients are likely. In chapter 2 we studied 
changes in active smoking, cessation plans and passive smoking in 380 CD and 295 UC 
patients using a written questionnaire. More ever smoking UC patients stopped smoking 
before diagnosis than CD patients (63 vs. 22%; p<0.001), resulting in 30% former smokers 
at diagnosis in UC and 13% in CD (p<0.001). The smoking cessation rates at and after 
diagnosis are equal between CD and UC. Half of the CD patients stopped smoking after 
diagnosis leading to fewer present smokers in CD than in a control population (26 (95% 
confidence interval: 21–30%) vs. 33%). For both CD (22 vs. 35%; p=0.044) and UC (24 
vs. 53%; p=0.024) continuing smokers after diagnosis were less often highly educated than 
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quitters. Cessation plans (89%), passive smoking in childhood and present passive smoking 
were not different between CD and UC patients. We conclude that there are no differences in 
changes in smoking behaviour at and after diagnosis between CD and UC patients, suggest-
ing a lack of knowledge by these patients about the link between their disease and smoking 
behaviour. However, CD patients seem less refractory to smoking cessation than the general 
population considering that half of the CD patients stopped smoking after diagnosis. There-
fore it is worthwhile putting energy in helping CD patients stop smoking. In both CD and UC, 
a higher education is associated with smoking cessation after diagnosis.
Studies about the role of smoking on the disease course of CD as well as UC give conflict-
ing results, and studies about the effect of passive smoking on the course of IBD are rare or 
non-existing. In chapter 3 we retrospectively studied the effects of active and passive smoking 
in 380 CD and 295 UC patients from a university hospital cohort. Smoking behaviour was 
defined by using the same questionnaire as in chapter 2, and data on the disease course 
was obtained from patient records. At diagnosis there were 52% smokers in CD, 41% in the 
general population, and 28% in UC. The number of present smokers in CD is lower than the 
present number of smokers in the general population (26 vs. 35%). No detrimental effects 
of active smoking on CD were observed, but passive smokers needed more frequently im-
munosuppressants and infliximab than non-passive smokers. Active smoking had beneficial 
effects on UC, indicated by reduced rates of colectomy, primary sclerosing cholangitis and 
backwash-ileitis in active smokers compared to never smokers, and higher daily cigarette 
dose correlated with less extensive colitis and a lower need for therapy. Furthermore, smoking 
cessation after diagnosis was detrimental for UC patients, indicated by increased needs for 
steroids and hospitalizations for patients that stopped smoking after diagnosis compared to 
before diagnosis. The conclusion of this study is that active smoking is a risk factor for CD, 
but does not affect the disease course. Passive smoking is detrimental for the outcome of CD 
patients. In UC, active smoking shows dose-dependent beneficial effects on the outcome. 
Our data suggest that passive smoking is a novel risk factor for CD.
The results of our study in chapter 3 were somewhat unexpected, mainly because the det-
rimental effect of active smoking on CD was not confirmed, but also because of the finding 
of opposite effects of active and passive smoking. Some of this could be caused by studying 
patients from a university hospital with an important referral function. Studying patients re-
ferred from other hospitals causes a selection bias, since patients with a more benign disease 
course could be underrepresented. The effects of smoking on the disease course could be so 
subtle, that they are more pronounced in patients with a benign disease course. In chapter 4 
we aimed to see whether the findings in chapter 3 could be confirmed in an IBD cohort from 
a regional hospital. We retrospectively studied the effects of active and passive smoking in 
128 CD and 192 UC patients from a regional hospital. We used the same methods as in 
chapter 3. At diagnosis there were 52% (95% confidence interval: 43–60%) smokers among 
CD patients, 40% in a control population and 25% (95% confidence interval: 18–31%) 
among UC patients. There were less former (19 vs. 31%, p=0.013) and never smokers at 
diagnosis (30 vs. 44%, p=0.009) in CD than in UC. No detrimental effects of active or pas-
sive smoking on the course of CD were observed. UC patients who continued smoking after 
diagnosis needed less often two or more hospitalizations than never smokers (5 vs. 25%, 
p=0.036). Otherwise no clear beneficial effects of active smoking on UC were observed. 
Passively smoking UC patients experienced more often extraintestinal manifestations (25 vs. 
7%, p=0.029) than non-passive smokers. We conclude that also in an IBD population from 
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a regional hospital smoking is a risk factor to develop CD and protects against developing 
UC. We found no detrimental effects of smoking on the disease course of CD and no clear 
beneficial effects on the course of UC.
Besides smoking behaviour, another important factor for the development of CD is the 
genetic background. During the last decade a still increasing number of genetic variants 
have been found to be associated with IBD, especially with CD. It is likely that the develop-
ment of CD is partly caused by an interaction between these genetic variants and smoking, 
but studies investigating this interaction are scarce. In chapter 5 we studied differences in 
disease associated genetic variants between CD patients stratified for active smoking at 
diagnosis and for passive smoking in childhood. We selected 19 confirmed genetic variants 
located in 14 CD-associated genes or loci, including three NOD2 variants. Genotyping data 
of these 19 CD-associated so-called single-nucleotide polymorphisms (SNPs) were avail-
able for 310 CD patients and 976 controls from previous studies by our group. We studied 
the allelic associations of these 19 CD-associated SNPs in CD patients stratified for active 
smoking at diagnosis and passive smoking in childhood. Data on active smoking at diag-
nosis and passive smoking in childhood were obtained through the previously mentioned 
written questionnaire and review of the medical charts. The loci associated in smoking, but 
not in non-smoking, CD patients were 5p13.1 (rs17234657), DLG5 (rs2165047), NKX2-3 
(rs10883365) and NOD2 (R702W). The loci associated in non-smoking, but not in smok-
ing, CD patients were IL23R (rs7517847), 5p13.1 (rs9292777), IRGM (rs13361189 and 
rs4958847), IL12B (rs6887695) and CCNY (rs3936503). PTPN2 (rs2542151) was only 
associated in the smoking CD cohort (p=0.04), and not in the entire cohort (p=0.23) or in 
the non-smoking CD cohort (p=0.80). In passively smoking CD patients, associations with 
13 SNPs in 9 loci were found, including PTPN2. In non-passively smoking CD patients, only 
associations with NOD2 (1007fsinsC and G908R) were found. In conclusion, we found dif-
ferent genetic associations in different groups according to active smoking at diagnosis and 
passive smoking in childhood. A part of these differences can be explained by the lack of 
power in this relatively small CD cohort. However, the difference in associated genes between 
smoking and non-smoking CD patients implies a complex gene–environment interaction. 
Therefore, genetic studies of CD should be stratified for smoking behaviour, as otherwise 
moderately associated genes such as PTPN2 can be missed.
It is unknown why smoking is beneficial for UC. One of the pathways involved in the ben-
eficial effects could be the heme-oxygenase 1 (HO-1) pathway. HO-1 is the rate-limiting 
enzyme involved in the breakdown of heme, yielding the end-products biliverdin, Fe2+ and 
carbon monoxide. Heme causes oxidative stress, while all three end-products have anti-
oxidative, anti-apoptotic and anti-inflammatory properties. Induction of HO-1 was beneficial 
in animal models of intestinal injury. Cigarette smoke (CS) is able to induce HO-1 in several 
human cells, but the effect of smoking on colonic HO-1 expression is unknown. Induction 
of colonic HO-1 by smoking could be beneficial for UC patients by protecting against de-
velopment of UC and/or by ameliorating inflammation in established UC. In chapter 6 we 
performed a laboratory study on the effects of smoking on the colonic expression of HO-1 
in vitro, in animals and in humans. For the in vitro part DLD-1 cells were incubated with 
cigarette smoke extract (CSE), for the animal part mice were exposed to CS, and for the 
human part colon biopsies of healthy human non-smokers and smokers were collected. 
HO-1 expression was evaluated by quantitative polymerase chain reaction (qPCR), western 
blotting and immunohistochemistry. Cytochrome P450 1A1 (CYP1A1) expression (qPCR) was 
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used as a positive control for exposure of the colon to CS. CSE dose-dependently induced 
HO-1 and CYP1A1 expression in DLD-1 cells. In mice and humans, colonic CYP1A1 mRNA 
expression was increased in subjects exposed to CS, but colonic HO-1 mRNA and protein 
expression were equal between controls and subjects exposed to CS. In the humans smoking 
exposure was in the therapeutic range for UC. The conclusion of this study is that CS does 
induce a CYP1A1 response, but not a HO-1 stress response in colonic epithelial cells. This 
indicates that CS does not exert its beneficial effect on UC via up-regulation of colonic HO-
1, but could trigger other protective mechanisms locally in the colon.
Literature about the role of smoking in recipients of liver transplants is scarce. The few re-
ports available about the effects of smoking on OLT recipients show that smoking is a risk 
factor for several complications and serious events after OLT. Considering this detrimental 
effect of smoking after OLT, it is disappointing that only two transplant centers have studied 
the smoking behaviour in OLT recipients. In chapter 7 we report about the smoking behav-
iour of OLT recipients before and after transplantation, and about the association of smok-
ing and the occurrence of malignancies and cardiovascular diseases after OLT. One of the 
aims was to define groups at risk for resuming smoking after OLT. All 401 adult patients 
with a follow-up of at least 2 years after OLT were included. Data were collected from the 
medical charts. A questionnaire about smoking habits at 4 time points before and after OLT 
was sent to all 326 patients that were alive, and 301 (92%) patients responded. Both before 
and after OLT, 53% of patients never used tobacco and around 17% were active smokers. In 
2007 28% of the Dutch population were active smokers. Of the active smokers during the 
evaluation for OLT, almost one-third succeeded in cessation, often during the waiting time 
for OLT. Twelve percent of former smokers restarted smoking, mainly after OLT. Especially 
former smokers who had succeeded in stopping tobacco use a relatively short time ago were 
at risk of relapse. Tobacco use was the highest in patients with alcoholic liver disease (52% 
were active smokers before OLT, and 44% after OLT) and the lowest in patients with primary 
sclerosing cholangitis (1.4% were active smokers before OLT). At 10 years, the cumulative 
rate of malignancies was 12.7% in active smokers versus 2.1% in non-smokers (P=0.019). 
No association with skin cancer or cardiovascular disease was found. In conclusion, before 
and after OLT about 17% of patients are active smokers. After OLT this percentage includes 
restarting former smokers and a decreasing number of active smokers transplanted for alco-
holic liver disease. Prevention programs should focus not only at active smokers, but also at 
former smokers, especially those who stopped smoking quite recently. The higher prevalence 
of malignancies in active smokers after OLT warrants intervention programs after OLT and 
regular screening for malignancies.
Future perspectives
Despite the enormous amount of studies on the effects of smoking on the disease course of 
CD and UC, it is still not clear which role smoking plays in the course of both diseases. One 
of the findings of this thesis is that we found no detrimental effect of smoking on the course 
of CD. This is not in line with some studies that found a clear detrimental effect. Probably, 
smoking is only detrimental for the course of CD for selected patients. The susceptibility of 
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patients could depend on gender, disease location and disease severity. For example, it is 
suggested that especially female CD patients are affected by smoking. In this thesis we could 
not confirm this. Future studies should focus on selecting patient groups that are susceptible 
to the effects of smoking. We were the first to study the effects of passive smoking on the 
course of IBD. We studied this in a population from a university hospital and a regional hos-
pital. We found a detrimental effect of passive smoking on CD patients from the university 
hospital, but could not confirm this in the regional hospital population. We need more stud-
ies on the effects of passive smoking on the course of IBD to determine the role of passive 
smoking.
In this thesis we have shown that the development of CD depends on an interaction be-
tween smoking and genetics. It is likely that the effects of smoking on the disease course 
also depend on the genetic background. Hopefully, future genetic studies are able to select 
genetic variants that make patients susceptible to the effects of smoking. At this moment the 
course of CD is unpredictable, but this might change in the near future. Members of our 
group showed that it might be possible to identify subgroups of CD patients with a severe 
prognosis based on the genetic variants. They found that an increasing number of risk alleles 
is associated with a more severe course of the disease.1 Future studies should aim to classify 
CD patients based on a combination of the genetic background and smoking behaviour. 
Hopefully, this gives the opportunity to identify specific patient groups and to adjust treat-
ment; some patients might benefit from early intervention and aggressive therapy, and other 
patients could be spared the side effects of unnecessary therapy.
From the findings from our study on the interaction between smoking and genetics, it is 
clear that specific environmental factors are necessary for specific genetic variants to con-
tribute to disease development. This is an important finding, as most genetic case – control 
studies are not stratified for environmental factors and are not matched with data on environ-
mental factors in control cohorts. In the future, we maybe able to find more CD-associated 
genes, and probably also UC-associated genes, by stratifying genetic studies for smoking 
behaviour and/or other environmental factors. This will be particularly true for associated 
genes with low odds ratios.
Although the effects of smoking on the development and course of IBD are already stud-
ied for decades, it is still unknown which pathways are influenced by smoking and which 
component(s) of cigarette smoke is/are responsible. In this thesis we studied the heme-ox-
ygenase 1 (HO-1) pathway. Though cigarette smoke induces HO-1 expression in in vitro 
experiments with DLD-1 cells, we found no effect of cigarette smoke on colonic up-regulation 
of HO-1 in mice and humans. However, this does not mean that the HO-1 pathway is not 
involved in the beneficial effect of smoking on UC, since smoking could exert its beneficial ef-
fects through an up-regulation of HO-1 in the lungs causing increased carboxyhemoglobulin 
levels. Several interventions studies in mice showed beneficial effects of carbon monoxide 
on intestinal injury.2-4 Hopefully, in the future intervention studies with carbon monoxide will 
proof to be beneficial in UC patients. In this thesis we showed that cigarette smoke reaches 
the colon, since colonic CYP1A1 expression is increased in smokers. Therefore, cigarette 
smoke may trigger other protective mechanisms locally in the colon, and future studies are 
needed to find these protective mechanisms.
Considering the possible detrimental effects of smoking on CD, one of the therapeutic 
goals in CD must be smoking cessation. In this thesis we showed that half of the CD patients 
stopped smoking after diagnosis, and we concluded that CD patients seem less refractory 
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to smoking cessation than the general population. A French study showed that after inter-
vention only 12% of smokers quit for more than 1 year, and only 10% achieved prolonged 
abstinence.5 A recent study suggested that the high knowledge about the risks of smoking to 
health and the low nicotine dependence in CD patients suggests that most patients with CD 
could be helped to stop smoking successfully in the IBD clinic without specialist treatment.6 
In contrast to this study, another study showed that CD patients had a higher rate of the 
smoking-linked personality characteristic “impulsive sensation seeking” which is associated 
with a poor smoking cessation rate.7 The authors of this study suggested that CD patients 
with this higher impulsive sensation seeking need specific strategies for smoking cessation. 
Future studies are needed to clarify if CD patients need special cessation programs and how 
these programs should look like.
Every gastroenterologist will agree that we should advise CD patients to stop smoking. 
However, the situation on this matter for UC patients is complicated. As long as we don’t 
know which component in cigarette smoke causes the beneficial effect on UC, it remains 
difficult what we should advise UC patients. It is important that we should not discourage 
patients with UC from stopping smoking, since on the long run patients are protected against 
smoking-related diseases; patients with UC had a decreased risk of lung cancer 8,9 and car-
diovascular disease 8,10 compared to patients with CD.
The second focus of this thesis is the role of smoking in OLT recipients. In patients who are 
under consideration for OLT, cessation of alcohol consumption is required to be eligible for 
OLT, especially for those with alcoholic liver disease. The question is whether smoking cessa-
tion should also be introduced as an eligibility criterion for OLT. We found in this thesis that 
before and after OLT about 17% of patients are active smokers, and that active smokers after 
OLT have a higher prevalence of malignancies. Considering other studies that also showed 
detrimental effects of smoking on the long course after OLT, smoking cessation should be a 
major goal after OLT. Future studies on the effects of smoking on acute complications after 
OLT, like hepatic artery thrombosis 11 and transplant failure, can answer the question whether 
smoking cessation should also be a major goal before OLT. Interesting is a recent study that 
showed that active smokers had a 92% higher rate of biliary complications than lifetime 
non-smokers.12 Considering this last study, and the remarkable low percentage of 1.4% ac-
tive smokers in the primary sclerosing cholangitis group as shown in this thesis, it would be 
interesting to study the effects of smoking on recurrent primary sclerosing cholangitis after 
OLT. However, because of the low number of tobacco users in this patient group, this will only 
be possible in a multicenter study group.
Concluding, studies provided us with a lot of knowledge on the effects of smoking on CD 
and UC, including the studies in this thesis. However, the true role of smoking on CD and UC 
is still not clear, and more important, we still do not know which mechanisms are involved by 
smoking. The last decade a still increasing number of genetic variants have been found to be 
associated with IBD. In thesis we showed an interaction between these genetic variants and 
smoking on the development of CD. These findings proof that future genetic studies on CD 
and UC should be stratified for smoking behaviour. In OLT recipients cardiovascular diseases 
and malignancies are important causes of morbidity and mortality. In this thesis we showed a 
high and constant number of smokers before and after OLT, and that smoking is associated 
with malignancies after OLT. These results warrant intervention programs for smoking cessa-
tion and regular screening for malignancies in OLT recipients.
Summary and future perspectives
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Samenvatting
Twee belangrijke groepen patiënten voor de maag-darm-leverarts zijn patiënten met chroni-
sche inflammatoire darmziekten (inflammatory bowel diseases – IBD) en met leverziekten. De 
twee belangrijkste chronische inflammatoire darmziekten zijn de ziekte van Crohn (ZvC) en 
colitis ulcerosa (CU); beide worden gekenmerkt door terugkerende episodes van ontsteking 
van het maagdarmkanaal. Bij de ZvC kan het gehele maagdarmkanaal zijn aangedaan, 
terwijl bij CU de ontsteking zich beperkt tot de dikke darm. Een ander opmerkelijk verschil 
tussen de ZvC en CU is het tegengestelde effect van roken; roken lijkt nadelig te zijn voor de 
ZvC, maar gunstig voor CU. Waarschijnlijk door dit opmerkelijk tegengestelde effect zijn er 
veel studies gedaan naar de rol van roken in IBD. De rol van actief roken op het ontwikkelen 
van IBD is duidelijk: het is een risicofactor voor het ontwikkelen van de ZvC, maar beschermt 
tegen CU. In tegenstelling tot de duidelijke rol van actief roken, is het onduidelijk wat de 
rol van passief roken op het ontwikkelen van IBD is. Verder zijn studies over de effecten van 
actief roken op het beloop van de ZvC en CU niet eenduidig. Meerdere studies toonden een 
nadelig effect van actief roken op het beloop van de ZvC en een gunstig effect op dat van 
CU, maar voor beide ziektes konden andere studies dit niet bevestigen. Ten slotte is de rol 
van passief roken op het beloop van de ZvC en CU onbekend.
Het is onbekend waarom roken nadelig is voor de ZvC en gunstig voor CU. Mogelijk 
betrokken mechanismen zijn de Toll-like receptor-4-afhankelijke pathway in macrofagen, 
de heme-oxygenase-1 (HO-1) pathway en trombogene effecten van tabak op de intestinale 
microvasculatuur. Het begrijpen van het mechanisme wordt gecompliceerd door de vele 
componenten in sigarettenrook. De meest bestudeerde componenten zijn nicotine en kool-
stofmonoxide, en beide hebben nadelige en gunstige effecten op darmontsteking.
Patiënten met leverziekten zijn een andere belangrijke groep. Levertransplantatie (LT) is een 
geaccepteerde behandeling voor eindstadium leverziekte. De prognose van de ontvangers 
van een LT is de laatste decennia verbeterd. De belangrijkste oorzaken van morbiditeit en 
mortaliteit na LT zijn maligniteiten en hart- en vaatziekten. Roken is een beruchte risicofactor 
voor verschillende maligniteiten en hart- en vaatziekten in de algemene populatie, maar stu-
dies over de rol van roken in ontvangers van een LT zijn schaars. De paar studies die er zijn 
over de effecten van roken na LT laten zien dat roken een risicofactor is voor verschillende 
complicaties en ernstige aandoeningen na LT. Helaas is er weinig bekend over het rookge-
drag van ontvangers van een LT.
Dit proefschrift is gefocust op de rol van actief en passief roken in IBD, en op de rol van 
roken in ontvangers van een LT.
Hoofdstuk 1 begint met een introductie over de rol van roken bij mensen met IBD en ontvan-
gers van een LT, en geeft een overzicht van de onderzoeksdoelen van dit proefschrift.
Gezien het tegengestelde effect van roken op de ZvC en CU, treden er na diagnose bij pa-
tiënten met de ZvC en CU waarschijnlijk verschillende veranderingen op in rookgedrag. In 
hoofdstuk 2 hebben we veranderingen in actief roken, stopplannen en passief roken bestu-
deerd in 380 patiënten met de ZvC en 295 met CU. Hiervoor gebruikten we een schriftelijke 
enquête. Van de ooit rokende UC patiënten stopten meer met roken voor de diagnose dan 
ZvC patiënten (63 vs. 22%; p<0.001), wat leidde tot 30% ex-rokers ten tijde van diagnose 
bij CU en 13% bij de ZvC (p<0.001). Het percentage dat stopte met roken ten tijde van en 
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na diagnose was gelijk voor de ZvC en CU. De helft van de ZvC patiënten stopte met roken 
na de diagnose wat leidde tot minder huidige rokers bij de ZvC dan in een controle popu-
latie (26 (95% betrouwbaarheidsinterval: 21–30%) vs. 33%). In geval van zowel de ZvC (22 
vs. 35%; p=0.044) als CU (24 vs. 53%; p=0.024) waren patiënten die na diagnose door-
rookten minder vaak hoogopgeleid dan de stoppers. Stopplannen (89%), blootstelling aan 
sigarettenrook in de kindertijd en huidig passief roken waren niet verschillend tussen ZvC en 
CU patiënten. Wij concluderen dat er geen verschillen zijn in veranderingen in rookgedrag 
tussen ZvC en CU patiënten ten tijde van en na diagnose, wat suggereert dat deze patiënten 
niet goed op de hoogte zijn van de link tussen hun ziekte en rookgedrag. Toch lijken ZvC 
patiënten vatbaarder voor het stoppen met roken dan de algemene populatie aangezien de 
helft van de ZvC patiënten stopte met roken na diagnose. Dus is het geen verspilde energie 
ZvC patiënten te helpen met het stoppen met roken. Bij zowel ZvC als CU patiënten is een 
hogere opleiding geassocieerd met stoppen met roken na diagnose.
Studies over de rol van roken op het ziektebeloop van zowel de ZvC als CU laten tegen-
strijdige resultaten zien, en studies over de effecten van passief roken op het beloop van IBD 
zijn zeldzaam of afwezig. In hoofdstuk 3 hebben we retrospectief de effecten van actief en 
passief roken bestudeerd in 380 patiënten met de ZvC en 295 met CU uit een academisch 
ziekenhuis cohort. Voor het definiëren van rookgedrag gebruikten we dezelfde enquête als 
in hoofdstuk 2, en data over het ziektebeloop werden verkregen door statusonderzoek. Ten 
tijde van diagnose rookte 52% van de ZvC patiënten, 41% in een controlepopulatie, en 28% 
van de CU patiënten. Het aantal huidige rokers bij de ZvC is lager dan in de algemene po-
pulatie (26 vs. 35%). Er werden geen nadelige effecten van actief roken op het beloop van 
de ZvC gezien, maar passieve rokers hadden vaker immuunsuppressiva en infliximab nodig 
dan patiënten zonder blootstelling aan passief roken. Actief roken had gunstige effecten op 
CU, wat bleek uit een lager aantal colectomieën, en minder vaak primaire scleroserende 
cholangitis en backwash-ileitis in actieve rokers dan in nooit-rokers. Daarnaast was een 
hoger aantal sigaretten per dag gecorreleerd met een minder uitgebreide ontsteking van de 
dikke darm en een geringere behoefte aan therapie. Stoppen met roken na diagnose was 
nadelig voor CU patiënten aangezien patiënten die na diagnose stopten vaker steroïden en 
opnames nodig hadden dan patiënten die voor diagnose stopten. De conclusie van deze 
studie is dat actief roken een risicofactor is voor het krijgen van de ZvC, maar het ziektebe-
loop niet beïnvloedt. Passief roken is nadelig voor het beloop van ZvC patiënten. Voor CU 
heeft actief roken dosisafhankelijke gunstige effecten op het beloop. Onze data suggereren 
dat passief roken een nieuwe risicofactor is voor de ZvC.
De resultaten van hoofdstuk 3 waren enigszins onverwacht, vooral doordat het nadelige 
effect van actief roken op de ZvC niet werd bevestigd, maar ook door de tegengestelde 
effecten van actief en passief roken. Deels zou dit veroorzaakt kunnen zijn door het bestude-
ren van patiënten uit een academisch ziekenhuis met een belangrijke referentiefunctie. Het 
bestuderen van patiënten die verwezen zijn vanuit andere ziekenhuizen kan leiden tot een 
selectiebias, want patiënten met een gunstiger ziektebeloop kunnen ondervertegenwoordigd 
zijn. De effecten van roken op het beloop kunnen zo subtiel zijn, dat zij meer uitgesproken 
zijn in patiënten met een gunstig beloop. Het doel van hoofdstuk 4 was om te zien of de 
bevindingen van hoofdstuk 3 bevestigd konden worden in een IBD cohort uit een regionaal 
ziekenhuis. We hebben retrospectief de effecten van actief en passief roken onderzocht in 
128 patiënten met ZvC en 192 met CU uit een regionaal ziekenhuis. Hiervoor werden 
dezelfde methoden als in hoofdstuk 3 gebruikt. Ten tijde van diagnose rookte 52% (95% 
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betrouwbaarheidsinterval: 43–60%) van de ZvC patiënten, 40% in een controle populatie 
en 25% (95% betrouwbaarheidsinterval: 18–31%) van de CU patiënten. Er waren minder ex-
rokers (19 vs. 31%, p=0.013) en nooit-rokers ten tijde van diagnose (30 vs. 44%, p=0.009) 
bij ZvC dan bij CU. Er werden geen nadelige effecten van actief en passief roken op de 
ZvC gezien. CU patiënten die doorrookten na diagnose hadden minder vaak twee of meer 
opnames nodig dan nooit rokers (5 vs. 25%, p=0.036). Voor de rest werden er geen duide-
lijke gunstige effecten van roken op CU gezien. Passief rokende CU patiënten hadden vaker 
extra-intestinale manifestaties (25 vs. 7%, p=0.029) dan patiënten zonder blootstelling aan 
passief roken. We concluderen dat ook in een IBD populatie van een regionaal ziekenhuis 
roken een risicofactor is voor het ontwikkelen van de ZvC en beschermt tegen CU. We von-
den geen nadelige effecten van roken op het ziektebeloop van de ZvC en geen eenduidig 
gunstige effecten op het beloop van CU.
Naast rookgedrag is de genetische aanleg ook een andere belangrijke factor voor het ont-
wikkelen van de ZvC. Het laatste decennium is een nog steeds groeiend aantal genetische 
varianten gevonden die geassocieerd zijn met IBD en vooral de ZvC. Het is waarschijnlijk 
dat de ontwikkeling van de ZvC wordt beïnvloedt door een interactie tussen deze genetische 
varianten en roken, maar er zijn weinig studies die dit hebben onderzocht. In hoofdstuk 5 
hebben we verschillen in ziektegeassocieerde genetische varianten onderzocht tussen ZvC 
patiënten gestratificeerd voor actief roken bij diagnose en voor passief roken in de kindertijd. 
We selecteerden 19 bevestigde genetische varianten in 14 ZvC-geassocieerde genen of 
loci inclusief drie NOD2 varianten. Genotype data van deze 19 ZvC-geassocieerde zoge-
naamde “single-nucleotide” polymorfismen (SNPs) waren beschikbaar van 310 ZvC patiën-
ten en 976 controles uit eerdere studies door onze groep. We bestudeerden de allelische 
associatie van deze 19 SNPs in ZvC patiënten gestratificeerd voor actief roken bij diagnose 
en voor passief roken in de kindertijd. Data over actief roken bij diagnose en passief roken 
in de kindertijd werden verkregen door de eerder genoemde schriftelijke enquête en status-
onderzoek. De loci geassocieerd in rokende, maar niet in niet-rokende, ZvC patiënten wa-
ren 5p13.1 (rs17234657), DLG5 (rs2165047), NKX2-3 (rs10883365) en NOD2 (R702W). 
De loci geassocieerd in niet-rokende, maar niet in rokende, ZvC patiënten waren IL23R 
(rs7517847), 5p13.1 (rs9292777), IRGM (rs13361189 en rs4958847), IL12B (rs6887695) 
en CCNY (rs3936503). PTPN2 (rs2542151) was alleen geassocieerd in het rokende ZvC 
cohort (p=0.04), en niet in het gehele ZvC cohort (p=0.23) of in het niet-rokende ZvC 
cohort (p=0.80). In passief rokende ZvC patiënten werden associaties met 13 SNPs in 9 
loci gevonden, inclusief PTPN2. In ZvC patiënten niet blootgesteld aan passief roken werden 
alleen associaties gevonden met NOD2 (1007fsinsC en G908R). Concluderend vonden 
we verschillende genetische associaties in verschillende groepen, die zich van elkaar onder-
scheidden door al dan niet actief roken ten tijde van diagnose en al dan niet passief roken 
in de kinderleeftijd. Een deel van dit verschil kan verklaard worden door een gebrek aan 
“power” in dit relatieve kleine ZvC cohort. Toch impliceert het verschil in geassocieerde ge-
nen tussen rokende en niet-rokende ZvC patiënten een complexe gen-omgevingsinteractie. 
Daarom moeten genetische studies in de ZvC gestratificeerd worden voor rookgedrag, want 
anders kunnen minder sterk geassocieerde genen zoals PTPN2 gemist worden.
Het is onbekend waarom roken gunstig is voor CU. Eén van de mogelijk betrokken path-
ways is de heme-oxygenase-1 (HO-1) pathway. HO-1 is het snelheidsbeperkende enzym 
betrokken bij de afbraak van haem, wat leidt tot de eindproducten biliverdine, Fe2+ en 
koolstofmonoxide. Haem veroorzaakt oxidatieve stress, terwijl alle drie de eindproducten 
9137
antioxidatieve, antiapoptotische en anti-inflammatoire eigenschappen hebben. Inductie van 
HO-1 had een gunstig effect in diermodellen met darmschade. Sigarettenrook (SR) is in 
staat tot het induceren van HO-1 in verschillende humane cellen, maar het effect van roken 
op HO-1 expressie in de dikke darm is onbekend. Inductie van HO-1 in de dikke darm zou 
gunstig kunnen zijn voor CU patiënten door bescherming te bieden tegen de ontwikkeling 
van CU en/of door ontsteking in geval van actieve CU te verminderen. In hoofdstuk 6 heb-
ben we een laboratoriumonderzoek verricht naar de effecten van roken op de expressie van 
HO-1 in de dikke darm in vitro, in dieren en in mensen. Voor de in vitro proeven werden 
DLD-1 cellen geïncubeerd met sigarettenrook extract (SRE), voor de dierproeven werden 
muizen blootgesteld aan SR en voor het humane deel werden dikke darmbiopten verzameld 
van gezonde niet-rokers en rokers. HO-1 expressie werd beoordeeld met quantitative poly-
merase chain reaction (qPCR), western blotting en immunohistochemie. Cytochroom P450 
1A1 (CYP1A1) expressie (qPCR) werd gebruikt als een positieve controle voor blootstelling 
van de dikke darm aan SR. SRE induceerde dosisafhankelijk HO-1 en CYP1A1 expressie 
in DLD-1 cellen. In muizen en mensen was de CYP1A1 mRNA expressie in de dikke darm 
verhoogd bij expositie aan SR, maar HO-1 mRNA en eiwit expressie in de dikke darm was 
gelijk tussen controles en aan SR geëxposeerden. In de humane studie was de expositie aan 
SR in de therapeutische bandbreedte voor CU. De conclusie van deze studie is dat SR een 
CYP1A1 respons induceert, maar geen HO-1 stress respons in epitheel cellen van de dikke 
darm. Dit wijst erop dat het gunstige effect van SR op UC niet verloopt via opregulatie van 
HO-1 in de dikke darm, maar SR zou wel andere beschermingsmechanismen lokaal in de 
dikke darm in gang kunnen zetten.
Literatuur betreffende de rol van roken in ontvangers van een levertransplantatie (LT) is 
schaars. De paar beschikbare studies over de effecten van roken in LT ontvangers tonen 
dat roken een risicofactor is voor verschillende complicaties en ernstige aandoeningen na 
LT. Gezien dit schadelijke effect van roken na LT is het teleurstellend dat slechts twee trans-
plantatiecentra het rookgedrag van LT ontvangers hebben onderzocht. In hoofdstuk 7 be-
schrijven we het rookgedrag van LT ontvangers voor en na transplantatie, en de associatie 
tussen roken en het optreden van maligniteiten en cardiovasculaire ziekten na LT. Eén van 
de doelen was het definiëren van groepen die vatbaar zijn voor herstarten van roken na 
LT. Alle 401 volwassen patiënten met een follow-up van minimaal twee jaar na LT werden 
geïncludeerd. Data werden verzameld vanuit medische statussen en naar alle 326 levende 
patiënten werd een enquête gestuurd over het rookgedrag op vier momenten voor en na LT. 
Op de enquête reageerden 301 (92%) patiënten. Zowel voor als na LT gebruikte 53% van 
de patiënten nooit tabak en ongeveer 17% was actief roker. Ter vergelijk, in 2007 rookte 
28% van de Nederlandse bevolking. Bijna een derde van de actieve rokers tijdens evalu-
atie voor LT lukte het om te stoppen met roken, meestal tijdens de wachtlijstperiode voor LT. 
Twaalf procent van de ex-rokers begon opnieuw met roken, vooral na LT. Vooral ex-rokers 
die nog maar een relatief korte tijd geleden gestopt waren, waren vatbaar voor een terug-
val. Tabakgebruik was het hoogst in patiënten met een alcoholische leverziekte (52% was 
actief roker voor LT en 44% na LT) en het laagst in patiënten met primaire scleroserende 
cholangitis (1,4% was actief roker voor LT). Tien jaar na LT was het cumulatieve aantal 
maligniteiten 12,7% in actieve rokers tegen 2,1% in niet-rokers (P=0.02). Er werd geen as-
sociatie gevonden met huidkanker of cardiovasculaire ziekten. Concluderend, voor en na 
LT zijn ongeveer 17% van de patiënten actief roker. Na LT omvat dit percentage ex-rokers 
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die weer zijn begonnen en een afname van actieve rokers bij patiënten met een alcoholische 
leverziekte. Preventieprogramma’s moeten zich niet alleen focussen op actieve rokers, maar 
ook op ex-rokers en dan vooral ex-rokers die recent zijn gestopt. Gezien het hoge aantal ma-
ligniteiten in actieve rokers na LT zijn een interventieprogramma na LT en frequente screening 
voor maligniteiten nodig.
Toekomstperspectieven
Ondanks de enorme hoeveelheid studies over de effecten van roken op het ziektebeloop van 
de ZvC en CU is het nog steeds onduidelijk welke rol roken precies speelt in het beloop van 
beide ziekten. In dit proefschrift konden wij geen nadelig effect van roken vinden op het be-
loop van de ZvC, terwijl andere studies wel een duidelijk nadelig effect vonden. Waarschijn-
lijk is roken alleen nadelig voor bepaalde patiënten met de ZvC. Dit zou afhankelijk kunnen 
zijn van geslacht, en lokalisatie en ernst van de ziekte. Eerder is al gesuggereerd dat roken 
vooral voor vrouwelijke ZvC patiënten nadelig is, maar dit konden wij in dit proefschrift niet 
bevestigen. Toekomstige studies zouden meer moeten focussen op het identificeren van spe-
cifieke patiëntgroepen die vatbaar zijn voor de effecten van roken. Wij hebben als eerste de 
effecten van passief roken op het beloop van IBD onderzocht, en hebben dit gedaan in zowel 
een cohort van een academisch als van een regionaal ziekenhuis. In het academische cohort 
vonden we een nadelig effect van passief roken bij ZvC patiënten, maar konden dit niet 
bevestigen in het regionale cohort. Er zijn dan ook meer studies over de effecten van passief 
roken op het beloop van IBD nodig om de precieze rol van passief roken te bepalen.
In dit proefschrift hebben we laten zien dat de ontwikkeling van de ZvC mede afhankelijk 
is van een interactie tussen roken en de genetische aanleg. Ook de effecten van rook op het 
ziektebeloop zouden weleens afhankelijk kunnen zijn van de genetische aanleg. Hopelijk lukt 
het in de toekomst genetische varianten te selecteren die patiënten vatbaar maken voor de 
effecten van roken. Op dit moment is het nog niet mogelijk het beloop van de ZvC te voor-
spellen, maar er gloort hoop. Onderzoekers van onze groep toonden aan dat het misschien 
mogelijk wordt subgroepen van ZvC patiënten met een ernstige prognose te identificeren op 
basis van de genetische varianten. Zij vonden een associatie tussen een toenemend aantal 
risicoallelen en een ernstiger ziektebeloop.1 Komende studies moeten zich richten op het 
classificeren van ZvC patiënten gebaseerd op genetische aanleg in combinatie met rook-
gedrag. Hopelijk kunnen we hierdoor specifieke patiëntgroepen identificeren en hierop de 
behandeling aanpassen; sommige patiënten kunnen baat hebben bij vroege interventie en 
agressieve medicatie, terwijl andere patiënten juist de bijwerkingen van onnodige medicatie 
bespaard kan blijven.
Uit onze studie naar de interactie tussen roken en genetische aanleg blijkt duidelijk dat 
specifieke omgevingsfactoren nodig zijn om bepaalde genetische varianten te laten bijdra-
gen aan het ontwikkelen van ziekte. Dit is een belangrijke bevinding, omdat de meeste 
genetische patiënt-controle studies niet gestratificeerd zijn voor omgevingsfactoren en niet 
gecorreleerd zijn aan omgevingsfactoren in de controle cohorten. Als deze studies wel gaan 
stratificeren voor rookgedrag en/of andere omgevingsfactoren is het misschien mogelijk om 
nog meer ZvC-geassocieerde genen te vinden en waarschijnlijk ook meer CU-geassocieerde 
genen. Dit zal vooral het geval zijn voor geassocieerde genen met lage odds ratio’s.
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Hoewel de effecten van roken op het ontstaan en beloop van IBD al decennia worden 
bestudeerd, is het nog steeds onbekend welke pathways beïnvloed worden door roken en 
welke component(en) in sigarettenrook verantwoordelijk is/zijn. In dit proefschrift hebben we 
de heme-oxygenase 1 (HO-1) pathway bestudeerd. Hoewel sigarettenrook HO-1 expressie 
induceerde in in vitro experimenten met DLD-1 cellen, vonden we geen effect van roken op 
de expressie van HO-1 in de dikke darm van muizen en mensen. Dit betekent echter niet dat 
de HO-1 pathway niet betrokken is bij de gunstige effecten van roken op CU, want roken 
zou zijn gunstige effecten ook kunnen uitoefenen door opregulatie van HO-1 in de longen 
met als gevolg verhoogde koolstofmonoxide concentraties. Verschillende interventiestudies 
in muizen hebben gunstige effecten van koolstofmonoxide aangetoond bij darmschade.2-4 
Wellicht blijkt uit toekomstige interventiestudies dat koolstofmonoxide ook gunstig is voor 
CU patiënten. In dit proefschrift hebben we aangetoond dat sigarettenrook de dikke darm 
bereikt gezien de verhoogde CYP1A1 expressie in de dikke darm van rokers. Dit betekent dat 
sigarettenrook andere lokale beschermingsmechanismen dan HO-1 in de dikke darm kan 
beïnvloeden. Om deze te vinden, zijn meer studies nodig.
Gezien de mogelijk nadelige effecten van roken op de ZvC moet stoppen met roken één 
van de therapeutische doelen zijn. In dit proefschrift toonden we aan dat de helft van de bij 
diagnose rokende ZvC patiënten stopte met roken na de diagnose en we concludeerden dat 
ZvC patiënten vatbaarder zijn voor het stoppen met roken dan de algemene populatie. Een 
Franse studie vond dat na interventie het slechts 12% van de rokers lukte om meer dan een 
jaar te stoppen en slechts 10% lukte het om langdurig te stoppen.5 Een recente studie sugge-
reerde dat de meeste ZvC patiënten succesvol in de IBD kliniek geholpen kunnen worden bij 
het stoppen met roken zonder specialistische hulp, aangezien ZvC patiënten een hoog ken-
nisniveau over de risico’s van roken op de gezondheid hadden en een lage nicotineafhan-
kelijkheid.6 In tegenstelling tot deze studie toonde een andere studie aan dat ZvC patiënten 
vaker het rookgerelateerde persoonlijkheidskenmerk “impulsive sensation seeking” hadden, 
wat juist geassocieerd is met een geringe neiging tot stoppen.7 De auteurs van deze studie 
suggereren dat ZvC patiënten met “impulsive sensation seeking” specifieke strategieën voor 
het stoppen met roken nodig hebben. Bovenstaande studies zijn dus niet eenduidig en er zijn 
meer studies nodig om opheldering te krijgen of ZvC patiënten speciale stopprogramma’s 
nodig hebben en hoe deze er dan uit moeten zien.
Elke maag-darm-leverarts is het er mee eens dat het advies aan ZvC patiënten is om te 
stoppen met roken. De situatie voor CU is gecompliceerder. Zolang we niet weten welke 
component in sigarettenrook de gunstige effecten veroorzaakt, blijft het moeilijk wat we CU 
patiënten moeten adviseren. Het is wel belangrijk dat we CU patiënten die willen stoppen 
met roken niet ontmoedigen, want op de lange termijn worden ze beschermd tegen rookge-
relateerde ziekten; CU patiënten hadden een verminderd risico op longkanker 8,9 en hart- en 
vaatziekten 8,10 vergeleken met ZvC patiënten.
De tweede focus van dit proefschrift is de rol van roken in LT ontvangers. Voor patiënten 
die geëvalueerd worden voor LT is stoppen met alcohol een voorwaarde om in aanmerking 
te komen voor LT, vooral voor diegenen met een alcoholische leverziekte. De vraag is of 
stoppen met roken ook ingevoerd moet worden als een voorwaarde om in aanmerking te 
komen voor LT. In dit proefschrift vonden wij dat voor en na LT ongeveer 17% van de pa-
tiënten actief roken en dat actieve rokers na LT zes keer vaker maligniteiten hebben. Andere 
studies hebben ook ongunstige effecten van roken op de lange termijn na LT aangetoond en 
dus moet (blijvend) stoppen met roken een belangrijk doel na LT zijn. Of stoppen met roken 
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ook een belangrijk doel vóór LT moet zijn, zal moeten blijken uit toekomstige studies over 
de effecten van roken op acute complicaties na LT, zoals trombose van de leverslagader 11 
en transplantaatfalen. Interessant is een recente studie waarin actieve rokers een 92% hoger 
aantal galwegcomplicaties hadden na LT dan nooit-rokers.12 Mede gezien deze laatste studie 
en het opmerkelijk lage aantal van 1,4% actieve rokers bij primaire scleroserende cholangitis 
zoals aangetoond in dit proefschrift, zou het interessant zijn om te bestuderen wat het effect 
van roken is op recidief van primaire scleroserende cholangitis na LT. Dit zal echter alleen 
mogelijk zijn in een multicenter studie gezien het lage aantal rokers in deze patiënt groep.
Concluderend kan worden gesteld dat studies, inclusief die in dit proefschrift, ons hebben 
voorzien van enorm veel kennis over de effecten van roken op de ZvC en CU. De ware rol 
van roken bij ZvC en CU is echter nog steeds niet duidelijk en nog belangrijker, we weten 
nog steeds niet welke mechanismen door roken worden beïnvloed. Het laatste decennium 
is een nog steeds groeiend aantal genetische varianten gevonden die geassocieerd zijn 
met IBD. In dit proefschrift hebben we een interactie aangetoond tussen deze genetische 
varianten en rookgedrag op de ontwikkeling van de ZvC. Deze bevindingen bewijzen dat 
toekomstige genetische studies in de ZvC en CU gestratificeerd moeten worden voor rook-
gedrag. In LT ontvangers zijn hart- en vaatziekten en maligniteiten belangrijke oorzaken van 
morbiditeit en mortaliteit. In dit proefschrift toonden we een hoog en constant aantal rokers 
voor en na LT, en een associatie tussen roken en maligniteiten na LT. Dit maakt dat een in-
terventieprogramma voor het stoppen met roken en frequente screening op maligniteiten bij 
rokers nodig zijn in LT ontvangers.
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